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INTRODUCTION 
The simultaneous occurrence of lipid accumulation in human tendon 
(xanthoma) and arterial wall (atheroma) has already been described in 
the 19th century (1). Subsequently, these phenomena were discovered to 
be attended with elevated levels of serum cholesterol (2,3). Twenty years 
ago Khachadurian (4) proposed a distinction between a homozygous and a 
heterozygous form of familial hypercholesterolemia, which disease would 
be inherited as a mono-genetic autosomal dominant trait of one gene, 
individuals inheriting two mutant alleles (homozygotes) being more 
severely affected than those inheriting one mutant allele (heterozygotes). 
Circulating cholesterol is bound to apoproteins. It is possible to 
separate these lipoproteins in a number of fractions by ultracentri fu-
gation. Familial hypercholesterolemia is characterized by an increased 
concentration of low density lipoprotein (LDL) in serum (5). The under-
lying cause is a relative or absolute deficiency of LDL-receptors on the 
cell membrane. As a result, LDL uptake by the cells is decreased or even 
absent (6). Heterozygotes for familial hypercholesterolemia have one 
normal gene and one abnormal gene for the LDL-receptor. Their cells 
produce only half the normal number of LDL-receptors. There is also more 
LDL produced in these patients than in normal subjects. Together, these 
phenomena lead to a sustained twofold to threefold elevation in serum LDL 
levels from the time of birth and cause symptomatic atherosclerosis 
beginning in the fourth to fifth decade of life. Homozygotes, who have 
inherited two mutant genes, synthesize few (receptor-defective) or no 
(receptor-negative) functional LDL-receptors. Simultaneously, over-
production of lipoprotein occurs. These two abnormalities lead to a six-
fold to eightfold elevation in serum LDL levels as early as the 20th week 
of intrauterine gestation; as a consequence, symptomatic coronary athero-
sclerosis typically develops before the age of 20 years (7). 
Current therapy in hypercholesterolemia, familial or otherwise, is 
aimed at a maximal reduction of serum cholesterol. However, it has not yet 
been proven unequivocally that reduction of serum cholesterol will lead 
to a lower mortality as a result of ischemic heart disease. Therapy often 
consists of a drug and dietary regimen. In heterozygotes, these measures, 
which are essentially for life, may result in a considerable lowering of 
serum cholesterol. However, the effects are reported to be insufficient 
in extensive clinical trials (8). The homozygous form of the disease has 
failed to respond adequately to a variety of drug regimens. Here, more 
radical measures in the form of plasma exchange (9) or portacaval shunt 
(10) have shown some effects. 
Twenty years ago Buchwald and coworkers performed their first 
partial ileal bypass (PIB) operation as a therapeutic measure for hyper-
cholesterolemia (11). Bypassing the distal third of the small intestine 
interrupts the enterohepatic cycle of bile acids. This leads to a 
considerable bile acid drainage in the faeces resulting in an enhanced 
conversion of cholesterol to bile acids in the liver. The decreased 
intra-hepatocellular cholesterol concentration causes an increase in 
both cholesterol synthesis and lipoprotein-cholesterol uptake from the 
circulation. The net result is a considerable lowering of serum 
cholesterol. This working mechanism is similar to that of bile acid 
resins like cholestyramine. PIB induces an obligatory, sustained 
decrease in the level of serum cholesterol of patients with the 
heterozygous form of familial hypercholesterolemia (12). However, the 
procedure is not without side effects (cf. chapter II). So far, 
construction of a PIB for heterozygous hypercholesterolemia has only 
been reported for 108 cases (cf. chapter I, B). This number appears 
rather small considering the fact that the incidence of heterozygous 
familial hypercholesterolemia approximates 1 in 500 in Europe and the 
United States. Results of PIB in homozygous patients are still 
questionable. Seven patients were operated: serum cholesterol remained 
unaffected in 3, while in the other 4 a small but significant decrease 
occurred. 
Research on atherosclerosis has made extensive use of animal models. 
Human atherosclerosis is more difficult to investigate than animal 
atherosclerosis. In man, the development of atherosclerotic plaques 
takes years necessitating long research periods. Some laboratory 
animals, especially the rabbit, can be made hypercholesterolemic by the 
addition of cholesterol to their food. This may result in enormously 
enhanced serum cholesterol levels, which cause atherosclerotic lesions 
to appear in a matter of weeks. Also, animals may be kept under strictly 
standardized conditions. Thus, the influence of hypercholesterolemia 
2 
alone can be studied properly because of the absence of other risk 
factors like, for instance, hypertension and overweight. Finally, 
research into the human disease is severely hampered by the fact that 
direct visualization and quantification of atherosclerosis remain 
impossible. One can only depend on angiography and other - non-invasive -
examinations of blood vessels, which give rather indirect information. 
Animal models allow isolation and direct analysis of tissues at any time 
during the experimental period. A great number of questions concerning 
atherosclerosis still has to be answered, for instance, about the way 
atherosclerosis originates, about the beneficial effects of lipid-
lowering procedures on the progression of atherosclerosis and about the 
possibilities of inducing regression. Animal models will be essential 
to answer these questions. 
Buchwald et al. (13) have shown that PIB may prevent both hyper-
cholesterolemia and atherogenesis in cholesterol-fed rabbits. The same 
animal model was used recently to study the effects of PIB on lipo-
protein metabolism (14) and receptor binding of lipoproteins (15). 
Although Constanti ni des et al. (16) did point out the similarities 
between human atherosclerosis and atherosclerosis in cholesterol-fed 
rabbits, at least one fundamental difference remains. Human familial 
hypercholesterolemia is endogenous, while hypercholesterolemia in 
cholesterol-fed animals is exogenous. 
Very recently, Watanabe (17) has developed a rabbit model with 
familial hypercholesterolemia, the Watanabe heritable hyperlipidemic 
(WHHL) rabbit. Both lipoprotein patterns and atherosclerotic plaque 
characteristics show great similarity to those observed in man (18). 
Thus, WHHL rabbits are a new and exciting animal model to study problems 
concerning familial hypercholesterolemia (19). 
The experiments described in this thesis have been conducted 
primarily in order to investigate the effects of a partial ileal 
bypass operation on hypercholesterolemia and atherogenesis, both in 
cholesterol-fed and in WHHL rabbits. The lipid-lowering potential of 
surgical intervention in WHHL rabbits has also been compared to that of 
drug therapies. Finally, the effect of nifedipine, a calcium-antagonist 
which reportedly inhibits atherogenesis in cholesterol-fed rabbits, has 
been examined in WHHL rabbits. 
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Chapter I 
THE TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA 
BY PARTIAL ILEAL BYPASS SURGERY 
A review of the literature 
J.L.M. van Niekerk, Th. Hendriks and H.H.M, de Boer 
Neth.J.Med., in press 
1.1 Introduction 
Familial hypercholesterolemia is one of the most frequently occur-
ring hereditary diseases in man. Its mode of inheritance is autosomally 
dominant. The incidence of heterozygous familial hypercholesterolemia 
is 1 in 500. Serum cholesterol is enhanced 2-3 fold and from an age of 
35 years onwards the patient runs an increased risk of atherosclerosis. 
The incidence of the homozygous form of the disease is only 1 in 10 . 
Here, serum cholesterol is increased 4-6 fold and a myocardial 
infarction almost invariably occurs before the age of 20 years (1). 
While it still remains to be proven unequivocally that lowering of 
the serum cholesterol level will improve morbidity and mortality of 
cardiovascular diseases, current treatment of these patients aims to 
induce a maximal decrease in serum cholesterol. Therapy consists mostly 
of a diet with or without drug regimen. However, there is also the 
possibility of surgical therapy. Partial ileal bypass (PIB) has been 
performed for the first time in 1963 by Buchwald and, at present, his 
group has treated more than 100 patients with various forms of hyper-
lipoproteinemia (2). So far, 108 cases of familial hypercholesterolemia 
have been described in the literature, which were treated by means of a 
PIB: 101 heterozygous patients (2,3,5-10,12-18) (cf. Table I) and 7 
homozygous patients (2,4,9,11,12). 
It is our aim to review the effects and side effects of PIB and to 
discuss its suitability as a mode of treatment in heterozygous as well 
as homozygous hypercholesterolemia. 
1.2 Operation technique 
The length of the small intestine is measured from the ligament of 
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Treitz to the ileocecal valve. The distal 2 m are bypassed. If the length 
of the small intestine surpasses 6 m, the bypass should involve 33% of the 
total length (2). Thus, the length of the PIB is considerably shorter than 
the length of the jejunoileal bypass for morbid obesity, where more than 
80% of the total small intestinal length is shunted. 
The intestine is transsected at the appropriate position. The distal 
end is closed and attached to the coecum in order to prevent invagination. 
The proximal end is anastomosed end-to-side to the ascending colon, 6 cm 
from the appendix base. The appendix is removed routinely. 
1.3 Cholesterol metabolism 
Only 30-50% of dietary cholesterol is resorbed, mainly in the 
jejunum. Free cholesterol is solubilized in the intestinal lumen by bile 
salts, absorbed by passive diffusion and subsequently incorporated into 
chylomicrons. Chylomicrons are converted to chylomicron remnants, which 
are ultimately cleared in the liver (19). Apart from the uptake of 
200-300 mg dietary cholesterol, the human body daily synthesizes another 
800-1000 mg cholesterol (20). Although almost every cell possesses the 
capacity for cholesterol synthesis, by far the most active synthesis 
takes place in the liver (21). 
There are several ways in which the liver disposes of cholesterol 
(22): 
1. Quantitatively most important is the conversion into bile acids which 
are subsequently removed in the bile. A large part of the bile acids 
is absorbed again in the ileum (enterohepatic cycle) (23). A minor 
part leaves the body as faecal acid steroids. 
2. Cholesterol may also be directly excreted into the bile and sub-
sequently removed with the faeces as a neutral steroid. 
3. Cholesterol can also be secreted by the liver to the blood, incorpo-
rated in very low density lipoprotein (VLDL) particles. In the 
circulation, these are converted to intermediate density lipoprotein 
(IDL) and subsequently to low density lipoprotein (LDL). The latter 
particles are then taken up in cells elsewhere. For this purpose 
membranes possess specific receptors, but uptake may also take place 
by means of a non-receptor mediated process (20,24). A minor loss of 
body cholesterol thus occurs through shedding of cells and excretion 
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of steroids in urine. 
The receptor specif ic LDL uptake is lowered by approximately 50% 
in heterozygous fami l ia l hypercholesterolemia (24). The impaired 
degradation of LDL cholesterol results in an enhanced concentration of 
serum LDL cholesterol , since feed-back regulation of LDL cholesterol 
production stays at the same level or sometimes increases. The increased 
LDL cholesterol synthesis and the diminished f ract ional catabolic rate 
give r ise to a new equi l ibr ium with an increase of the serum LDL 
cholesterol level to higher plateau (24). 
1.4 Effect of PIB on cholesterol metabolism 
The principal ef fect of PIB is the interrupt ion of the entero-
hepatic cycle of b i le acids, result ing in a considerable b i le acid 
drainage in the faeces. Because of the feed-back inh ib i to ry effect of 
b i l e acids on the enzyme 7-ct hydroxylase in the l i v e r , reduction of the 
b i le acid pool w i l l lead to induction of th is ra te - l im i t ing enzyme and 
thus give r ise to enhanced conversion of cholesterol to b i le acids (21). 
The resul t ing decreased intra-hepatocel lular cholesterol concentration 
causes induction of the LDL receptors at the ce l l surface and thus 
enhances extraction of cholesterol from the c i r cu la t i on . Indeed, i t has 
been shown that PIB stimulates the receptor mediated uptake of LDL 
cholesterol in patients with heterozygous fami l ia l hypercholesterolemia 
(16). However, the lowered concentration of cholesterol in the hepato-
cytes w i l l also increase the ac t i v i t y of HMG-CoA reductase, the rate-
l im i t i ng enzyme in cholesterol synthesis (21). A four- to f i ve - fo ld 
increase of de novo cholesterol synthesis has been reported to occur 
af ter PIB (2). S t i l l , the net result of b i le acid drainage through PIB 
is a considerable lowering of serum cholesterol . 
1.5 Side effects of PIB 
While b i le acid drainage is pr imari ly responsible for the beneficial 
decrease of serum cholesterol , i t also causes a major side e f fec t , 
diarrhoea, which may or iginate in two ways: 
1. Bi le acids which enter the colon i r r i t a t e the mucosa, result ing in 
secretion of water and sa l ts . Sometimes prur i tus ani occurs. This b i le 
acid diarrhoea responds well to treatment with b i le acid-binding 
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resins, e.g. cholestyramine. Obviously, the need for additional 
cholestyramine is a drawback, since one of the aims of surgical 
intervention is to do away with the necessity of further use of drugs. 
2. A shortage of bile acids affects fat absorption in the small intestine. 
Fatty acids and hydroxy-fatty acids enter the colon and irritate the 
mucosa. This also contributes to diarrhoea by causing secretion of 
water and salts. The resulting 'fatty acid' diarrhoea will only occur 
in the presence of a strong bile drainage and will thus be coupled to 
'bile acid' diarrhoea (25). Binding of bile acids with specific 
resins may further prevent fat digestion and increase 'fatty acid' 
diarrhoea (25). 
It is difficult to evaluate the seriousness of diarrhoea after PIB 
from the literature. Diarrhoea probably should be defined as an increase 
in 24-hour output of faecal material, but this parameter has only been 
investigated once so far (18). Most authors reporting on the incidence 
of diarrhoea after PIB describe only the frequency of defaecation. 
Sometimes even this remains unmentioned or classification is made into 
none, few or many complaints. Probably, diarrhoea is underreported. 
Table I reviews the available data. If the frequency of defaecation was 
reported, a frequency higher than 5 times a day is classified as serious. 
Diarrhoea which has been treated with drugs is also classified as 
serious. In the first year after operation a majority of the patients 
suffers from diarrhoea: a considerable number has many complaints. For 
this reason intestinal continuity was restored in 3 patients, PIB being 
essentially reversible. In the remaining patients treatment with anti-
diarrhoeal drugs or cholestyramine, if necessary in combination with a 
low fat diet, was sufficient. As yet, it remains a matter of doubt 
whether the diarrhoea is of a temporary nature (2,18). 
The increased synthesis of bile acids is unable to fully compensate 
for the loss of bile acids. Therefore, the daily amount of bile acids 
entering the small intestine decreases, causing a moderate steatorrhoea 
(18) (9 g faecal fat/24 h, a 200% increase 18 months after PIB). 
A minor increase in renal excretion of oxalic acid has also been 
reported for some patients (18). Various hypotheses exist to explain 
this phenomenon (26). So far, urolithiasis has not been found after PIB, 
whereas it is a common phenomenon after jejunoileal bypass (27). It 
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should be emphasized that follow-up in this respect does not exceed 
2 years. 
Ileal bypass or ileal resection, performed on indications other than 
hypercholesterolemia, have been reported to increase the incidence of 
gallstones (28). Formation of gallstones was seen once after PIB for 
hypercholesterolemia (2). 
After PIB a small but significant (+ 6%) reduction in body_weight 
is transitory in most patients. Only in obese patients does PIB lead to 
greater loss of weight (2,18). 
Malabsorption of Yitami.n_B12 may also occur after PIB (29). 
Schillings tests did show a 6% excretion in 24 h, indicating a reduced 
absorption in the intermediate zone (8,29). Therefore, patients routinely 
receive injections of vitamin B12 on a regular basis. Folic acid 
absorption remained unchanged (8). Deficiencies of other vitamins have 
not been reported after PIB. 
Reduced absorption of dietary calcium has also been observed, but 
bone densitometry does not indicate premature osteomalacia after 18 
months (13). This phenomenon remains unmentioned in studies with a 
longer follow-up period. 
Finally, the possible occurrence of disorders of liyer_function 
should be discussed, because of the high incidence of progressive 
histologic liver damage (29%) with cirrhosis {7%) encountered after 
jejunoileal bypass for morbid obesity (27). So far, only one study has 
mentioned a transient increase of serum alanine aminotransferase after 
PIB (18). In four other studies (2,11,14,17), one of which covers a ten 
year follow-up period (2), no changes in liver enzymes were found. Liver 
histology after PIB has as yet remained uninvestigated. It seems un-
justified to draw a parallel between jejunoileal bypass and PIB with 
respect to subsequent liver pathology. Firstly, because patients with 
morbid obesity often display liver disorders already before operation 
(30) and, secondly, since the etiology of liver failure after jejunoileal 
bypass is still poorly understood (27,30). If excessive uptake of litho-
cholic acid or production of bacterial toxins in the bypassed intestinal 
segment are important in the process leading to liver failure after 
jejunoileal bypass, this complication might possibly be expected to 
occur to some extent after PIB as well. However, other factors which 
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have been mentioned to be potentially damaging to the liver after jejuno-
ileal bypass, e.g. deficiencies of fatty acids and protein, as well as 
unbalance between carbohydrate and fat absorption, might be expected to 
contribute less after PIB. 
Thus, at the present time one can only state that, in view of the 
experience with jejunoileal bypass, long-term follow-up of liver 
functions seems necessary after PIB. The, relatively few, data obtained 
so far do not indicate liver failure to be a significant feature after 
PIB. 
Buchwald has described the operation mortality and morbidity in 101 
hyperlipidemic patients, 24 of which with familial hypercholesterolemia. 
One patient died 4 days post-operatively from a myocardial infarction. 
A small bowel obstruction from adhesive bands was seen in 3 cases (2). 
From the other 84 patients described in the literature with a PIB 
for familial hypercholesterolemia (3,5-10,11-18), one died 8 days post-
operatively from aspiration pneumonia. In addition, 2 stenoses of the 
anastomosis were seen and anastomotic leakage occurred twice. Bleeding 
in the anastomosis, and also invagination of an unfixed ileum stump, 
were encountered twice. 
1.6 Lipid-lowering effects of PIB and of drug therapy 
The decrease of serum cholesterol induced by PIB in patients with 
heterozygous familial hypercholesterolemia varies between 33 and 40% 
(Table I). Serum cholesterol is lowered in all patients treated with 
PIB. It is a permanent effect and caused primarily by a decrease in 
LDL cholesterol; HDL cholesterol and serum triglycerides remain 
essentially unaffected (16,18,31). In almost all cases, dietary therapy 
was prescribed, both before and after operation. Diet alone may induce 
a lowering of serum cholesterol of maximally 10-15% in type II patients 
(32). 
Current drug therapies often involve the bile acid resins 
cholestyramine or colestipol, which may effectively lower serum 
cholesterol by 15-25%. A combination of different classes of drugs may 
result in an even greater decrease in serum cholesterol. Clofibrate 
lowers cholesterol synthesis and increases faecal cholesterol excretion. 
In combination with cholestyramine it induces an additional lowering of 
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TABLE I 
Results of PIB in Heterozygous Type I I Familial Hypercholesterolemia, ng = not given; 0 = no diarrhoea; 
+ = few complaints of diarrhoea; ++ = serious diarrhoea/rrore than 5 times a day/drugtherapy 
Author Number of 
patients 
Average Average 
follow-up serum-
period choles-
terol 
before 
operation 
Average 
serum-
choles-
terol 
after 
operation 
Average 
decrease 
(%)serum 
choles-
terol 
Average 
decrease 
{%) LDL-
choles-
terol 
Severity of diarrhoea 
ng 
1st year 
after 
operation 
0 + ^ 
more than 
1 year after 
operation 
ng 0 + ++ 
11 authors 
with series 
with less 
than 10 
patients 
(ref. 3, 
5-10,13, 
14,16,17) 
Buchwald 
and Moore 
(ref.2,30) 
Miettinen 
(ref.12) 
Russell 
(ref.15) 
Faegerman 
(ref.18) 
45 
24 
12 
10 
10 
2 months/ 
3 years 
1 year 
3 weeks 
1 year 
1,5 year 
10.3 
9.9 
12.7 
11.6 
11.9 
6.9 
5.9 
8.2 
7.7 
7.4 
33 
40 
35 
34 
38 
ng 
45 (n=10) 
ng 
36 
46 
10 
18 
12 
2 19 
3 
3 
14 24 10 11 
3 10 0 12 
12 
7 10 
5 
2 
5 
CJ 
serum cholesterol with approximately 10% (32). Nicotinic acid has also 
been reported to result in a strong additional effect if used in 
combination with colestipol (33). It has been shown very recently that 
compactin (ML-236B), a competitive inhibitor of HMG-CoA reductase, and 
cholestyramine have additive effects in reducing serum cholesterol in 
heterozygous patients with familial hypercholesterolemia (34). 
Generally speaking,one may expect the combined use of several drugs 
to result, under optimal conditions, in a lowering of serum cholesterol 
with 30-40%. Reduction of serum cholesterol by PIB is mostly greater, 
sometimes similar, but never smaller than the reduction obtained with 
previous diet and drug therapies. In those cases where the effects of 
PIB and drugs were equal, the length of the bypass was usually less than 
2 m. Direct comparison of PIB and cholestyramine treatment shows a 
significantly greater lowering of serum cholesterol after PIB (12,16). 
It remains to be investigated if a combination of PIB and an inhibitor 
of HMG-CoA reductase also shows additive lipid-lowering effects. 
1.7 PIB in homozygous familial hypercholesterolemia 
So far, surgical intervention in patients with homozygous familial 
hypercholesterolemia has been mainly by portacaval shunt. Average 
decrease of serum cholesterol in 45 patients was 43%. However, portacaval 
shunt is not without risks (35). 
A PIB has only been constructed in 7 homozygous patients. Serum 
cholesterol remained unaffected in 3 patients, while in the other 4 
decrease varied from 13 to 25%. A possible explanation for these divergent 
results may be that homozygous type II patients fall into 2 classes: a 
group entirely without LDL receptors (receptor-negative) and a group with 
2-25% of the normal number of receptors (receptor-defective) (24). Since 
PIB induces a lowering of serum cholesterol by means of a stimulation of 
LDL receptor activity, it might be expected to be effective only in the 
latter group, which still has retained the capacity to synthesize 
receptors. Animal experiments in our laboratory support this hypothesis 
(36). 
1.3 Discussion 
A discussion of the merits of surgical therapy for familial hyper-
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cholesterolemia should start by considering the question: should 
lowering of serum cholesterol indeed be the primary aim of treatment 
or, in other words, does a decrease of serum cholesterol indeed delay, 
inhibit or even reverse the process of atherosclerotic plaque formation? 
This question is not yet unequivocally answered. So far, randomized 
clinical trials have not established if drug-induced lowering of serum 
cholesterol, both as a primary or a secundary preventive measure, 
lowers the incidence of coronary disease. However, the observed 
decreases in serum cholesterol were minimal (about 10%). 
Most of the studies did include patients with all forms of hyper-
lipoproteinemia (37). It should be pointed out that hypercholesterolemia 
is most clearly seen as a risk factor in patients with familial hyper-
cholesterolemia, particularly in the homozygous form. Hopefully, the 
United States Cholestyramine Trial, a primary intervention study in 
3810 patients with familial hypercholesterolemia, will provide an answer 
in 1984. Buchwald's group has started a trial to examine the effects 
of PIB as a secundary preventive measure. Their aim is to bring together 
500 patients, which have suffered a myocardial infarction and meet a 
number of criteria concerning serum cholesterol, body weight id. Half of 
these will, at random, receive a PIB and the possible beneficial effects 
on incidence and seriousness of cardiovascular diseases will be evaluated 
after 4 years (38). It has been reported very recently that PIB causes 
regression of coronary lesions, which were quantitated by means of 
coronary angiography (39). 
Our own experimental work with the WHHL rabbit, a new model for 
familial hypercholesterolemia, shows that PIB significantly reduces 
atherosclerosis and may thus potentially be a beneficial therapy (36). 
Although medical and surgical therapy have not yet been compared directly 
in the same patients, it appears that a combination of drugs may possibly 
result in a lowering of serum cholesterol equivalent to that induced by 
PIB. Therefore, one might wonder if there exist indications for PIB at 
all. In our opinion this question should be answered affirmatively. 
Treatment by means of a drug regimen, which is essentially for life, is 
certainly not without side effects and asks for great patient cooperation. 
The results reported in the literature concern patients with more than 
average motivation, which were kept under close scrutiny during therapy. 
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I f used by average pat ients, which are seen by a physician less 
frequently, patient cooperation and thus lowering of serum cholesterol 
w i l l be less than optimal and therefore the ef fect w i l l nearly always be 
smaller than the obligatory decrease induced by PIB. For instance, i t has 
been shown that treatment with b i l e acid-binding resins does resul t in 
a decrease of serum cholesterol of 15-25% i f re la t i ve ly small groups of 
patients were studied. However, the ef fect was only about 10% in more 
extensive c l i n i ca l t r i a l s (40). 
In conclusion, PIB should be considered as a mode of treatment for 
fami l ia l hypercholesterolemia: 
- i f drug therapy gives an insuf f i c ien t lowering of serum cholesterol , 
- i f drug therapy induces too many side effects or 
- when the patient prefers a one-off operation to l i f e - long drug therapy. 
However, the fact that PIB w i l l invariably resul t in subsequent diarrhoea, 
which seriousness is d i f f i c u l t to predic t , necessitates a careful 
comparison of detriment and benefit of t h i s , essent ial ly reversible, 
surgical intervent ion. 
Furthermore, long-term follow-up studies on PIB are needed to 
evaluate the side-effects and complications, par t icu lar ly possible l i ve r 
function disturbances and l i ve r f a i l u r e , frequently seen af ter je junoi lea l 
bypass. 
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1.9 Summary 
In the literature 108 patients have been described with a partial 
ileal bypass for familial hypercholesterolemia. Surgical intervention in 
these patients has led to a permanent lowering of serum cholesterol levels 
with 33-40%. Operation technique and working-mechanisms in relation to 
cholesterol metabolism are described, together with side effects, 
particularly diarrhoea and possible liver function disorders. The 
suitability of partial ileal bypass as a mode of treatment in both 
heterozygous and homozygous familial hypercholesterolemia is discussed. 
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Chapter II 
BREEDING RESULTS OF RABBITS WITH FAMILIAL HYPERCHOLESTEROLEMIA: 
EFFECTS OF AGE AND SEX ON SERUM LIPIDS 
J.L.M. van Niekerk, J.P. Koopmans and Th. Hendriks 
Ζ. Versuchstierk., in press 
II. 1 Introduction 
Familial hypercholesterolemia in man is inherited as a mono-genetic 
autosomal dominant trait of one gene, individuals inheriting two mutant 
alleles (homozygotes) being more severely affected than those inheriting 
one mutant allele (heterozygotes) (Fredrickson et al, 1978). The 
Watanabe heritable hyperlipidemic rabbit (WHHL rabbit) is a recently 
developed animal model which could be very valuable for studies on 
familial hypercholesterolemia. The rabbits show structural deformities 
of LDL receptors which appear similar to those encountered in the human 
disease (Goldstein and Brown, 1982; Shimada et al, 1981). All animals 
display spontaneous aortic atherosclerosis at the age of 5 months 
(Watanabe, 1980), which trait is postulated as autosomal recessive 
(Watanabe, 1977). So far, data on breeding and description of genetic 
traits of these animals have been scarce. We have bred WHHL rabbits by 
crossing with New Zealand White (NZW) rabbits and subsequent back-
crossing. The present paper supplies data on 100 consecutive animals 
which were bred this way. In normo-cholesterolernie rabbits serum 
cholesterol is affected by age, sex, season, lactation and gravidity 
(Roberts et al, 1974). We have investigated the effects of age and sex 
on serum lipids in WHHL homozygotes and WHHL heterozygotes to further 
characterize this animal model. 
II.2 Materials and methods 
Male homozygote WHHL rabbits (a generous gift from Dr. Y. Watanabe) 
were mated with female NZW rabbits and the resulting WHHL heterozygotes 
were crossed back with their father. At the age of 6 weeks the animals 
obtained by this second crossing were weaned in groups and at the age 
of 10 weeks they were caged individually. The temperature in the animal 
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room was between 21 and 25 С and the room was i l luminated 12 hours a day. 
This way possible effects of season, lactat ion and grav id i ty were 
eliminated. The rabbits were fed ad l i b i t u m with cholesterol-free 
pellets (diet LK04, Hope Farms, Woerden, The Netherlands). At the age 
of 12 weeks body weight, serum cholesterol and serum t r ig lycer ides were 
measured af ter an overnight-fast. At the age of 17 weeks serum l i p o ­
proteins were determined in a number of male and female WHHL rabbi ts . 
Blood samples were taken by an a r t e r i a l punction in the ear a f t e r 
ρ 
injection of 0.25 mg Hypnorm /kg body weight in order to cause sedation 
and vasodilatation. Cholesterol in serum was analysed with the CHOD-PAP 
method (Röschlau et al, 1974; Trinder, 1969) and triglycerides by an 
enzymatic method (Garland and Rändle, 1962). Lipoproteins were separated 
by density gradient ultracentrifugation in a swinging bucket rotor 
(Demacker et al, 1978). The fractions of the VLDL, LDL, HDL were isolated 
on the basis of the coloured band distributions (Terpstra et al, 1981). 
II.3 Results 
Figure 1 shows the distribution of serum cholesterol levels, 
measured at the age of 12 weeks, in 100 littermates from crossings 
between heterozygote mothers and homozygote WHHL fathers. The animals 
were described as heterozygote or homozygote if their serum cholesterol 
was lower or higher, respectively, than 6.0 mmol/1. This way 34 rabbits 
were considered to be homozygotes (19 males and 15 females) while the 
remaining 66 rabbits (33 males and 33 females) were designated hetero-
zygotes. Among the heterozygotes males showed a significantly higher 
serum cholesterol than females. Among homozygotes no sex difference of 
serum cholesterol was found (Table I). Heterozygote males showed a 
significantly higher serum triglyceride level, while in homozygote 
rabbits again no difference between sexes was measured. 
Bodyweight in homozygote male and female rabbits tended to be lower 
as compared to heterozygote animals, but this difference was not 
significant (1553 + 111 g vs. 1611 + 226 g for males, ρ = 0.10 and 
1509 + 134 g vs. 1618 + 229 g for females, ρ = 0.07; two-sided unpaired 
Wilcoxon test). The distribution of cholesterol over the various serum 
lipoprotein fractions was measured in 6 male and 8 female homozygotes at 
the age of 17 weeks. Cholesterol concentrations in VLDL, LDL and HDL 
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FIGURE 1 
Serum cholesterol levels of 100 l i t termates from heterozygote mothers 
crossed with homozygote WHHL fathers 
2 4 6 8 10 12 14 16 18 20 22 24 26 
Serum-cholesterol (mmol/I) 
f ract ions were 3.71 + 1.28, 8.06 + 3.63 and 0.21 + 0.08 mmol/1, 
respect ively, in male and 2.28 + 0.47, 6.80 + 2.22 and 0.18 + 0.08 mmol/1, 
respect ively, in female rabbi ts. The differences between sexes were not 
s ign i f i can t (unpaired two-sided Wilcoxon t e s t , 5% leve l ) . 
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TABLE 1 
A comparison of serum lipids and weight of 100 consecutive male and female rabbits raised after mating 
female WHHL-heterozygotes with male WHHL-homozygotes. Measurements were performed at the age of 12 weeks. 
Rabbits with serum cholesterol levels over 6 mmol/l were considered as homozygotes. Mean values are given 
with standard deviation. Differences between males and females were tested with a two-sided unpaired 
Wilcoxon test. 
heterozygotes (n=66) homozygotes (n=34) 
male (n=33) female (n=33) differences male (n=19) female (n=15) differences 
serum cholesterol 2.4 +1.0 1.8 +0.6 ρ < 0.01 15.9+3.7 13.7+3.8 η.s. 
(mmol/1) 
serum triglycerides 1.61+0.94 1.06+0.37 ρ < 0.01 3.95+2.06 3.82+2.45 η.s. 
(mmol/1) 
body weight 1611 + 226 1618 + 229 η.s. 1553 + 111 1509 + 134 η.s. 
(g) " _ 
TABLE 2 
Effect of age on serum l i p ids in various rabbit species. Only male animals were used for these measurements. 
Mean values are given with standard deviat ion. Changes in time are tested for signif icance with a two-sided 
paired Wilcoxon tes t . 
serum cholesterol ( imo l / l ) serum t r ig lycer ides (mmol/l) 
Age in months 3 9 differences 3 9 differences 
WHHL-homozygotes (n=6) 1 6 . 6 + 3 . 4 1 7 . 2 + 4 . 2 n.s. 4 . 7 5 + 2 . 2 4 3 . 0 4 + 0 . 3 8 n.s. 
WHHL-heterozygotes (n=7) 1 . 9 + 0 . 7 0 . 9 + 0 . 2 0.01<p<0.05 1 .65+0.39 1 .86+1.22 n.s. 
NZW (n=7) 1 . 5 + 0 . 1 0 . 9 + 0 . 1 0.01<p<0.05 0 .48+0 .13 0 .75+0 .16 0.01<p<0.05 
There was no difference in serum cholesterol and serum triglyceride 
levels, measured at ages 3 and 9 months, in male homozygote rabbits 
(Table 2). In male heterozygotes serum cholesterol had decreased 
significantly at 9 months, while serum triglycerides remained unchanged. 
Male NZW rabbits showed a significant decrease of serum cholesterol and a 
significant increase of serum triglycerides. If we compare the 3 months 
old heterozygotes with the NZW rabbits,described in Table 2, the serum 
cholesterol tends to be higher but the difference is not significant. 
However, the difference in serum cholesterol at 12 weeks between hetero­
zygotes and NZW rabbits is significant if the 7 NZW rabbits are compared 
with all (33) male heterozygotes (1.5 + 1.0 and 2.4 + 1.0 mmol/1, 
respectively; ρ < 0.01 for Wilcoxon unpaired one-sided test). Serum 
triglycerides in heterozygote rabbits were significantly higher than in 
NZW rabbits, both at the age of 3 and 9 months (0.01 < ρ < 0.05, one­
sided unpaired Wilcoxon test). 
II.4 Discussion 
Figure 1 suggests the rabbit population to be divided in two groups. 
However, there exists no well -defined separation between both 
populations. In man, homozygote familial hypercholestero!emiс patients 
have serum cholesterol levels between 18 and 31 mmol/1 (Havel, 1980) 
which is 3-4 times the normal value. Therefore, we consider rabbits as 
homozygotes if their serum cholesterol levels exceed 6 mmol/1, which 
value is about four times as high as the levels normally found in NZW 
rabbits. This rather arbitrary choice seems justified by the fact that 
19 heterozygotes (highest serum cholesterol, as determined at 12 weeks, 
5.2 mmol/1) sacrified at the age of 9 months had not developed any 
macroscopic plaques, while 10 homozygotes (lowest serum cholesterol, 
as measured at 12 weeks, 9.9 mmol/1) of the same age all showed 
significant plaque formation. 
Watanabe has drawn the line between heterozygotes and homozygotes 
at a serum cholesterol value, measured at weaning time, of 7.8 mmol/1 
(Watanabe, 1977). 
Originally, we also took the first blood samples at this stage of 
life. However, sampling frequently caused deaths and severe diarrhoea, 
possibly because this time is already stressful 1 for the animals. 
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Consequently, we routinely collected the first blood sample at the age 
of 12 weeks. Measurements of serum cholesterol levels in animals younger 
than 12 weeks showed that heterozygotes may display initial levels close 
to those observed in homozygotes (results not shown). However, these 
levels fall off rapidly, while they remain constant in homozygote animals. 
Therefore, if one wants to make a distinction between heterozygotes and 
homozygotes at weaning time (about 7 weeks), one should indeed increase 
the level of distinction from 6.0 mmol/1 to, for instance, 7.8 mmol/1. 
Dividing the 100 rabbits this way we find twice as much heterozygotes 
(66) as homozygotes (34). The sex distribution (Table 2) clearly indicates 
that the trait is inherited autosomally, confirming the observations of 
Watanabe (Watanabe, 1977) for pairing heterozygotes with homozygotes. 
Watanabe further reported an increased percentage of homozygotes after 
each generation. His second generation, which can be compared to the 
groups described in the present paper, contains also 34% homozygotes. 
However, third and fourth generations contain 46% and 71% homozygotes, 
respectively. 
Familial hypercholesterolemia in man is a mono-genetic disease 
which originates from an impaired LDL receptor. Since WHHL rabbits show 
a cellular phenotype which is LDL receptor deficient (Shimada et al, 1981) 
it seems reasonable to assume a similar mode of inheritance in these 
animals. In that case our mating program should yield equal numbers of 
heterozygotes and homozygotes. One could think of several reasons to 
explain the fact that this is clearly not the case, at least according to 
our definition of homozygotes as animals with persistent serum cholesterol 
levels over 6.0 mmol/1. Firstly, the perinatal mortality is higher in 
homozygotes than in heterozygotes. This seems unlikely since we found a 
postnatal mortality at 12 weeks of only 12%, while no significant 
differences between bodyweight of homozygotes and heterozygotes were 
observed. A second possibility is found in the occurrence of various 
mutant alleles specifying the structure of the LDL receptor, which 
situation has been postulated to exist in man (Goldstein and Brown, 1982) 
and results in different homozygote subtypes. One of these genotypes might 
display, at an age of 12 weeks, serum cholesterol levels lower than 
6.0 mmol/1. 
A third explanation is that serum cholesterol in normal rabbits is 
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coded by multiple genes, which are regulated by a control gen. This major 
control gen, which can also code for receptor activity, would be absent 
or defect in WHHL rabbits. Thus the genes in question come to full 
expression, resulting in high serum cholesterol levels. Because of the 
polygenic trait a wide range of values occurs. There can be some overlap 
between heterozygotes with one major control gen, which cannot suppress 
fully genes which code for high cholesterol in young animals and homo-
zygotes with unsuppressed genes which code for a low serum cholesterol. 
Because of this overlap it would be difficult to divide rabbits properly 
in hetero- and homozygotes at 12 weeks. This phenomenon may explain our 
finding of only 34% homozygote rabbits. By selecting WHHL homozygote 
rabbits at a relatively young age on the basis of high serum cholesterol, 
one selects also on the multiple uncontrolled genes, taking those who 
code for high serum cholesterol. This can also explain the higher 
incidence of homozygotes in later generations as found by Watanabe. The 
existence of these types of genes may also be responsible for the 
heritability of serum cholesterol in normal rabbits and the different 
responses to dietary cholesterol (Roberts et al, 1974; Zuthpen et al, 
1981). Thus, it remains to be seen whether the inheritance of familial 
hypercholesterolemia in WHHL rabbits is an autosomal monogenic trait 
with low penetrancy in heterozygotes or is caused by an autosomal major 
control gen which controls multiple genes. 
Twelve weeks old heterozygote rabbits display both an endogenous 
hypercholesterolemia and a hypertriglyceridemia, while after 9 months 
they have become normo-cholesterolemic but still retain their hyper-
triglyceridemia (Table 2). This transient hypercholesterolemia in 
WHHL rabbits was also noted by Watanabe (Watanabe, 1977). 
Fibroblast LDL receptor activity in WHHL heterozygote rabbits was 
almost equal to that in 'normal' rabbits, although there is some 
variability among cell lines (Shimada et al, 1981). The existence of 
different types of heterozygotes explains this finding. 
II.5 Summary 
Watanabe heritable hyperlipidemic (WHHL) rabbits were crossed with 
NZW rabbits. Subsequently, the female WHHL heterozygotes were back-
crossed with their fathers. Serum cholesterol and triglycerides were 
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measured in 100 consecutive animals from this generation. At the age of 
12 weeks they were divided into homozygotes (34) and heterozygotes (66) 
on the basis of their serum cholesterol level, animals with serum 
cholesterol over 6.0 mmol/1 being considered as homozygotes. The mode of 
inheritance is discussed. It could be either an autosomal mono-genic 
trait with low penetrancy in heterozygotes or an autosomal poly-gem'с 
trait with a major control gen. 
Serum lipids of homozygote rabbits are not affected by age and sex. 
In contrast, heterozygote rabbits display only a transient hyper­
cholesterolemia (males obtaining significantly higher serum cholesterol 
levels than females) but a persistent hypertriglyceridemia (again more 
pronounced in the male species). 
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Chapter Π Ι 
PARTIAL ILEAL BYPASS INHIBITS 
ATHEROSCLEROSIS IN WHHL RABBITS 
J.L.M. van Niekerk, P.N.M. Demacker, Th. Hendriks and H.H.M, de Boer 
Atherosclerosis 48 (1983) 243-252 
111.1 Summary 
The effectiveness of p a r t i a l i l e a l bypass (PIB) as a counter-
measure against atherosclerosis was evaluated in WHHL rabbits. The 
effects of PIB and sham-operation, each performed in f i v e animals, on 
serum l i p i d s , l ipoproteins and plaque formation were investigated. PIB 
resulted in an immediate and sustained decrease of 52% (range 29-67%) 
in serum cholesterol , while sham-operation had no e f f e c t . The main 
reduction was in LDL cholestero l ; VLDL cholesterol was lowered to a 
lesser extent. PIB also appeared to change the electrophoretic 
behaviour of t o t a l serum, very low density and low density l ipoproteins. 
Plaque formation, measured 30 weeks af ter operation in various aort ic 
segments and a r t e r i e s , was s i g n i f i c a n t l y reduced a f t e r PIB. 
I t is concluded that an induced lowering of serum cholesterol can 
prevent atherosclerosis in WHHL rabbits. Also, these animals must be 
considered as a model for the receptor-defective c e l l u l a r phenotype of 
homozygous f a m i l i a l hypercholesterolemia, not for the receptor-negative 
type, which is the only t r u l y genetically homozygous form. 
111.2 Introduction 
Partial ileal bypass (PIB) has been introduced by Buchwald (1) as a 
therapy for familial hypercholesterolemia. In heterozygous patients it 
induces a uniform and persistent reduction in levels of cholesterol, 
particularly LDL cholesterol (2), by stimulation of the LDL receptor 
uptake (3). The cholesterol-lowering potential of this surgical procedure 
in homozygous patients is still in doubt. So far, the procedure has been 
applied to 7 patients, resulting in an average reduction of serum 
cholesterol of 13%, varying from 0 to 38% (4-8). Homozygous patients also 
30 
exhibit a highly variable réponse to either diet or drug treatment (9). 
This lack of uniform response might be explained by the existence of 
different classes of homozygotes on the basis of cellular phenotype (10). 
Receptor-negative homozygotes completely lack the capacity to produce 
LDL receptors. Consequently, any therapy aiming at stimulation of 
production of LDL receptors by preventing uptake of bile acids in the 
ileum will fail to produce any results. On the other hand, such a therapy 
would be expected to work to some degree in receptor-defective homozygotes, 
whose cultured fibroblasts exhibit detectable LDL receptor activity. 
Recently, a unique model for homozygous familial hypercholesterolemia 
has become available, the Watanabe heritable hyperlipidemic (WHHL) rabbit 
(11), which has a deficiency of LDL receptors, analogous to that of the 
receptor-defective form of human familial hypercholesterolemia (12). The 
present report shows the marked effects of PIB on serum cholesterol 
levels in these LDL receptor-deficient animals. 
It is still a matter of controversy if lipid-lowering treatments 
prevent atherosclerosis (13). In man, it is only possible to evaluate 
the benefit of such treatment indirectly by angiographic assessment and 
non-invasive investigation of the vessel wall, other than comparing 
changes in morbidity and mortality. A more direct quantitative estimation 
of the effects of lipid-lowering therapies on the development of athero-
sclerosis is still required. However, in animal models, this more direct 
approach is already possible by a direct visualization and quantitation 
of the atherosclerotic plaques, comparing treated and non-treated 
animals. WHHL rabbits spontaneously develop severe atherosclerosis at 
the age of 5 months (11). We have examined the effects of reduction of 
serum cholesterol induced by PIB on plaque formation in the vessel wall. 
II 1.3 Material and methods 
Male WHHL rabbits were bred by crossing and back-crossing between 
New Zealand White (NZW) and WHHL rabbits (a gift from Dr. Y. Watanabe). 
At the age of 13 weeks, the rabbits underwent either a sham operation or 
a PIB. During the sham operation a laparotomy was performed, followed 
by measuring the total length of the small bowel, and a liver biopsy 
was taken. The PIB operation was essentially as described (1). The distal 
third of the small bowel was bypassed by a functional end-to-side 
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anastomosis between ileum and colon ascendens immediately above the 
ileocoecal valve. Again a l i v e r biopsy was done. A l l animals received 
a n t i b i o t i c s pre-operatively and for two days post-operatively. PIB 
animals were given an intramuscular vitamin B12 i n j e c t i o n every eight 
weeks. Al l animals were fed ad l ib i tum with a chow d i e t . Blood samples 
were col lected af ter an overnight f a s t . Cholesterol in serum was 
measured by the CHOD-PAP method (14,15) and t r i g l y c e r i d e s by an enzymatic 
method (16). Serum l ipoproteins were separated with agarose-gel e lectro­
phoresis (17). Lipoproteins were separated by density gradient u l t r a -
centr i fugat ion (18). The fract ions of the VLDL, LDL and HDL were isolated 
on the basis of the coloured band d is t r ibut ions (19). Alkaline phospha­
tase, alanine aminotransferase and γ-glutamyltransferase were measured 
as described in refs . 20, 21 and 22, respectively. 
The animals were k i l l e d 30 weeks af ter operation. The aortas with 
carot id and i l i a c branches and the truncus pulmonal is were dissected, 
l i v e r biopsies were taken and gal l bladder b i l e was sampled. In PIB 
animals we v e r i f i e d whether the bypass was s t i l l s u f f i c i e n t . In a l l 
animals concentrations of b i l e acids (23), cholesterol (16) and phospho­
l i p i d s (24) were measured in gal l bladder b i l e . The dissected aortas 
were divided i n t o segments: the aort ic arch, the part which ends 
immediately a f ter the l e f t subclavian artery branching, the thoracic 
aorta which runs to the branching of the mesenteric a r t e r y , and the 
abdominal aorta which ends at the b i f u r c a t i o n . Carotid a r t e r i e s , i l i a c a l 
arter ies and truncus pulmonalis were also dissected. The vessels were 
cut l o n g i t u d i n a l l y , f ixed in 10% formal in, coloured with Sudan IV, 
washed in 70% ethanol and water and kept in 10% formalin (25). They were 
placed between glass plates and photographed. The f i l m was projected 
onto a table with a coordinate system. The area of the segment was 
encircled and the coordinates of the perimeter were taken. A computer 
program calculated the surface area of the segment from these coordinates. 
Plaque surface was measured in the same way. 
S t a t i s t i c a l evaluation of the results described in Tables 1-4 was 
performed by means of a Wilcoxon two-sided unpaired t e s t . 
I I I . 4 Results 
Our stock of WHHL rabbits was chronically affected with Pasteurella 
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multocida, which proved to be very resistant to antibiotics. Mortality 
after sham and PIB operation was high, about 45% 3 months after operation. 
Most of these animals died within the first month after operation from 
an acute spreading of pasteurellosis from the nasal cavity to the lungs 
and midears. Mortality was similar after sham or PIB operation. This 
study concerns 5 sham-operated rabbits and 5 rabbits with a PIB. They 
were killed at the age of 43 weeks. After operation all animals gained 
weight, the sham group slightly more so than the PIB group, though the 
difference was not significant (Table 1). At the age of 12 weeks, 1 week 
before operation, serum cholesterol (14.7 + 3.4 mmol/l) and serum 
triglycerides (3.66 + 1.95 mmol/l) were strongly elevated as compared to 
7 male NZW rabbits of the same age (1.5 + 0.1 mmol/l and 0.49 + 0.12 
mmol/l, respectively). PIB resulted in a sharp and persistent decrease in 
serum cholesterol in 4 out of 5 rabbits (Fig. 1). One animal first 
responded, but 15 weeks after operation its serum cholesterol level 
started to rise again. Mean serum cholesterol values in the PIB group, 
as determined 15 and 20 weeks after operation, were significantly lower 
as compared to those in the sham-operated animals (Table 1). Although 
the PIB group showed a tendency to increased serum triglycerides, 
neither of the two groups displayed a significant change in serum 
triglycerides. 
The electrophoretic behaviour of whole serum and of both the VLDL 
and the combined LDL plus HDL fractions was examined 5 weeks after 
operation (Fig. 2). In whole serum of PIB rabbits a peak was observed, 
migrating in a pre-ß position, which was absent in the sham-operated 
controls (Fig. 2, upper panel). Also, the ß-band in the PIB rabbits 
appeared to be heterogenous. It consisted of two bands, the slower of 
which moved in a position closer to the human ß-band. Similarly, the 
VLDL fraction in sham-operated rabbits consisted of large amounts of 
ß-migrating lipoproteins with a heterogenous electrophoretic mobility 
(Fig. 2, middle panel). In contrast, the VLDL fraction of the PIB 
animals shows a more homogenous band. The electrophoretic mobility of 
the LDL + HDL fraction was slower in the PIB group than in the sham 
group: it had shifted slightly more to the electrophoretic mobility 
of human serum ß-lipoprotein (Fig. 2, lower panel). 
PIB significantly (p < 0.01) reduced LDL cholesterol in serum, if 
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TABLE 1 
Effect of PIB and Sham Operation on Weight and Serum Lipids (Values are 
Means + SD). 
sham (n=5) PIB (n=5) 
1404 + 141 
2016 + 129 
2146 + 51 
14.9 + 3.3 
5.4 + 0.9* 
7.4 + 3.4* 
2.90 + 0.98 
5.28 + 3.09 
4.93 + 1.50 
* Signi f icant (p < 0.01) difference between PIB and sham group 
compared to i t s level a f t e r sham operation (Table 2). Although the 
concentration of VLDL cholesterol also appeared to be lower af ter PIB, 
the difference was not s ign i f icant at the 5% l e v e l . The VLDL cholesterol/ 
serum t r ig lycer ides r a t i o in the sham group (0.8, Table 2) was strongly 
enhanced as compared to th is rat io in NZW rabbits of the same age and 
sex (0.2 + 0 . 1 , n=12). PIB lowered th is r a t i o s i g n i f i c a n t l y (p < 0.01). 
Serum t r i g l y c e r i d e s and HDL cholesterol were s imi lar in both groups. 
The same was found for alkal ine phosphatase, alanine aminotransferase 
and γ-glutamyltransferase and for the l i p i d composition in gal l bladder 
b i l e (Table 3). This composition also did not deviate from that obtained 
from NZW rabbits. Histologic examination of l i v e r biopsies, col lected 
pre-operatively and 30 weeks post-operatively, indicated no changes in 
e i ther group. 
Weight (g) 
before operation 
after operation: 
15.weeks 
30 weeks 
Cholesterol (mmol/1) 
before operation 
after operation: 
15 weeks 
30 weeks 
Triglycerides (mmol/1) 
before operation 
after operation: 
15 weeks 
30 weeks 
1518 
2250 
2328 
16.0 
15.0 
16.8 
4.34 
4.48 
2.56 
+ 243 
+ 201 
Τ 133 
+ 3.4 
+ 2.9* 
Τ 3.1* 
+ 2.33 
+ 2.81 
+ 0.75 
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FIGURE 1 
Effects of PIß and sham operation on serum cholesterol in WHHL rabbi ts. 
13-week-old rabbits underwent e i ther a PIB (0--0) or a sham (0 0) 
operation and serum cholesterol was measured every 3 weeks. 
serum-cholesterol mmol/l -
25 -1 
20 
15 -
10 
Sham 
•+-—• Pie 
—ι 1 1 1 
21 24 27 30 
weeKs after operation 
t 3 6 
bperation 
12 15 18 
origin |0 fn pre fl 
i 1 ι\ ι 
FIGURE 2 
Agarose gel electrophoresis of whole 
serum and of serum lipoprotein 
fractions from PIB and sham-operated 
rabbits. The electrophorectic mobility 
of whole serum (upper panel), VLDL 
(middle panel) and a combined HDL+ LDL 
fraction (lower panel) is represented 
by the densitometric scanning of the 
gel. 
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TABLE 2 
Serum Lipoproteins in WHHL Rabbits 5 Weeks After PIB or Sham Operation 
(Values are Means + SD) 
sham (n=5) PIB (n=5) 
Cholesterol 17.5+6.1* 5.7+1.4* 
Triglycerides 5.7 + 2.4 5.5 + 1.4 
VLDL cholesterol 4.6+2.5 2.5+1.0 
LDL cholesterol 10.9 + 3.2* 3.2 + 1.2* 
HDL cholesterol 0.3+0.1 0.2+0.1 
VLDL cholesterol 0.8+0.1* 0.4+0.1* 
Serum triglycerides 
Significant (p < 0.01) difference between PIB and sham group 
In the sham-operated rabbits most of the plaques were localized in 
the aorta arch. Fewer plaques were found more distally. Typical plaque 
formation was found at the origins of the intercostal branches of the 
thoracic aorta. There were always some plaques in the truncus pulmonalis, 
and occasionally also in the carotid arteries. No plaques were found 
distally from the aorta bifurcation (Table 4). Microscopic analysis 
revealed that the plaques contained foam cells, usually in combination 
with connective tissue and occasionally with calcifications. The endo-
thelial layer was always intact and there were no ulcerations or thrombus 
formations. The various parts of the aortas of the PIB rabbits showed 
a markedly reduced plaque formation (Table 4). Comparison of both groups 
revealed statistically significant differences, despite the fact that 
plasma cholesterol in one of the rabbits in the PIB group increased 
significantly 15 weeks after operation (Fig. 1). This apparently 
resulted in an increased plaque area, particularly in the aortic arch, 
as compared with the other PIB rabbits (Table 4). Most of the plaques 
were found in the aortic arch. All PIB rabbits showed plaque formation 
in this area. 
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TABLE 3 
Effects of PIB and Sham Operation on Liver Enzymes and Composition of 
Gall Bladder Bile in WHHL Rabbits. 
(Results are expressed as mean + SD. No difference, significant at the 
5% level, was found) 
sham PIB 
Liver enzymes (IU) 
Alkaline phosphatase 
before operation 
12 weeks after operation 
30 weeks after operation 
Alanine aminotransferase 
before operation 
12 weeks after operation 
30 weeks after operation 
γ-Glutamyltransferase 
before operation 
12 weeks after operation 
30 weeks after operation 
90 
48 
32 
27 
23 
39 
3 
3 
3 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
20 
7 
3 
6 
7 
12 
1 
1 
1 
91 + 
37 _+ 
24 + 
26 + 
40 + 
41 + 
3 + 
3 + 
1 + 
28 
16 
9 
2 
10 
13 
2 
1 
1 
Gall bladder bile (mmol/1) 
Bile acids 
Phospholipids 
Cholesterol 
242 + 59 
4.8 + 0.5 
1.5 + 0.4 
270 + 136 
4.2 + 3.0 
1.2 + 0.4 
III.5 Discussion 
In WHHL rabbits a deficiency of LDL receptors has been demonstrated 
on fibroblasts (12,26) and hepatocytes (26). This is supposedly the 
underlying cause for the increased LDL cholesterol concentration in 
serum. In addition, the LDL cholesterol synthesis is increased (27). We 
found that the VLDL fraction in sham rabbits was ß-migrating and that the 
VLDL cholesterol/serum triglycerides ratio was high. This points to an 
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TABLE 4 
Area of Plaques as Percentage of Total Vessel Area 
Aort ic 
arch 
Thoracic 
aorta 
Sham group 
64 
53 
31 
55 
34 
PIB group 
1 
4 
4 
3 
34 
Level of : 
0.03 
12 
14 
4 
6 
7 
1 
0 
0 
0 
2 
Abdominal 
aorta 
10 
8 
2 
3 
5 
0 
0 
0 
0 
3 
Arten'ae 
carotis 
7 
7 
2 
4 
0 
0 
0 
0 
0 
3 
àignificance (p-value) for di 
0.01 0.02 0.16 
Arteriae 
i l iacae 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
fferences 
-
ι Truncus 
pulmonal is 
8 
1 
4 
1 
4 
0 
0 
0 
0 
0 
between two 
<0.01 
Average 
; serum 
cholesterol 
(mmol/1) 
af ter 
operation 
22.0 
15.1 
15.5 
15.7 
13.5 
6.0 
6.4 
4.4 
6.0 
9.1 
groups 
0.01 
accumulation of VLDL remnants. B-VLDL is accumulated due to an impaired 
clearance of VLDL through a deficiency of LDL receptors, which leads to 
an enhanced conversion of VLDL to VLDL remnants (26). PIB interrupts the 
enterohepatic cycle of bile acids and thus essentially produces an effect 
similar to the administration of bile acid resins, though more effectively 
so (3,8). In heterozygous patients faecal bile acid loss increased more 
strongly after PIB than after cholestyramine (8). This induced shortage 
of bile acids causes an increased conversion of cholesterol into bile 
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acids and thus a high demand of cholesterol in the liver. The lowered 
concentration in the hepatocytes apparently results in stimulation of 
the LDL receptors (28), leading to a decrease in serum LDL cholesterol 
(3). We suggest that a similar stimulation of LDL receptors on liver 
cells occurs in WHHL rabbits after PIB. This underlines the fact that 
WHHL rabbits do not absolutely lack the LDL receptor, which means that 
this animal must be considered as a model for receptor-defective 
familial hypercholesterolemia and not for the receptor-negative form, 
which probably is the only truly genetically homozygous form of 
familial hypercholesterolemia. 
In type IIB, III, IV hyperlipoproteinemia the biliary cholesterol 
concentration is increased (29,30). However, this concentration was not 
increased in the WHHL rabbits, if compared with normal rabbits. 
Autopsy of the animals that did not survive the operation revealed 
that at the age of 13 weeks lesions in the aorta were usually absent. 
It seems that hemodynamic factors are important in determining the 
distribution of plaques. The bending of the blood flow in the aortic 
arch makes this region the most vulnerable aortic segment. Moreover, 
we observed plaque formation in the descending aorta at branching 
points, particularly at the intercostal branches. The orificia! lesions 
had a typical V configuration, where the lumen of the intercostal branch 
is localized in the sharp angle. After killing the animal whose serum 
cholesterol had started to rise again 15 weeks after PIB, we found a 
significant amount of bowel content in the bypassed ileum. The lumen 
immediately distal to the anastomosis was still closed by the ligature. 
Thus, it appears that reflux through the ileocoecal valve had occurred. 
In conclusion, we believe that the striking decrease in progression 
of atherosclerosis, observed after PIB in WHHL rabbits, is the direct 
result of a lowering of atherogenic VLDL remnants and LDL particles in 
serum. 
Acknowledgement 
The authors are grateful to the staff of the Central Animal 
Laboratory of the Medical Faculty (head: Dr. W.J.I, van der Gulden) 
for their excellent efforts in breeding the WHHL rabbits. 
39 
III.6 References 
1. Buchwald, H.A. Surgical operation to lower circulating cholesterol, 
Circulation, 28 (1963) 649. 
2. Moore, R.B., Buchwald, H.A. and Varco, R.L. The effect of partial 
ileal bypass on plasma lipoproteins. Circulation, 62 (1980) 469. 
3. Spengel, F.A., Jadhav, Α., Duffield, R.G.M., Wood, C.B. and 
Thompson, G.R. Superiority of partial ileal bypass over cholestyramine 
in reducing cholesterol in familial hypercholesterolaemia, Lancet, i 
(1981) 768. 
4. Balfour, J.F. and Kim, R. Homozygous type II hyperlipoproteinemia 
treatment, J.Amer.Med.Ass. 227 (1974) 1145. 
5. Buchwald, H.A., Moore, R.B. and Varco, L.R. Clinical status of the 
partial ileal bypass operation. Circulation, suppl. I, 49-50 (1974) 
1-22. 
6. Grundy, S.M., Ahrens, E.H. and Salen, G. Interruption of the entero-
hepatic circulation of bile acids in man - Comparative effects of 
cholestyramine and ileal exclusion of cholesterol metabolism, 
J.Lab.Clin.Med., 78 (1971) 94. 
7. Johnston, I.D.Α., Davis, J.Α., Moutafis, C D . and Myant, M.B. Ileal 
bypass in the management of familial hypercholesterolemia, Proc.Roy. 
Soc.Med., 60 (1967) 746. 
8. Miettinen, T.A. and Lempinen, M. Cholestyramine and ileal bypass in 
the treatment of familial hypercholesterolaemia, Europ.J.Clin.Invest., 
7 (1977) 509. 
9. Breslow, J.L., Spaulding, D.R., Lux, S.E., Levy, R.I. and Lees, R.S. 
Homozygous familial hypercholesterolemia, N.Engl.J.Med., 293 (1975) 
900. 
10. Goldstein, J.L. and Brown, M.S. The LDL receptor defect in familial 
hypercholesterolemia, Med.CI in.North Amer., 66 (1982) 335. 
11. Watanabe, Y. Serial inbreeding of rabbits with hereditary hyperlipid-
emia (WHHL-rabbit), Atherosclerosis, 36 (1980) 261. 
12. Shimada, Y., Tanzawa, K., Kuroda, M., Tsujita, Y., Arar, M. and 
Watanabe, Y. Biochemical characterization of skin fibroblasts derived 
from WHHL-rabbit, a notable animal model for familial hypercholestero! 
ernia, Europ.J.Biochem., 118 (1981) 557. 
40 
13. Ol iver, U.F. Coronary heart disease prevention - Tr ia ls using drugs 
to control hyperlipidemia. I n : N.E. Mi l le r and B. Lewis, (Eds.), 
Lipoproteins, Atherosclerosis and Coronary Heart Disease, Elsevier/ 
North-Holland, Amsterdam, 1981, p. 165. 
14. Röschlau, P., Bernt, E. and Gruber, W. Enzymatische Bestimmung der 
Gesamt-Cholesterins im Serum, Z.Klin.Chem.Klin.Biochem., 12 (1974) 
403. 
15. Trinder, P. Determination of glucose in blood using glucose oxidase 
with an al ternat ive oxygen acceptor, Ann.Clin.Biochem., 6 (1969) 24. 
16. Garland, P.B. and Rändle, P.J. A rapid enzymatic assay for g lycero l , 
Nature (Lond.), 196 (1962) 987. 
17. Demacker, P.N.M., Vos-Janssen, H.E., Van ' t Laar, A. and Jansen, A.P. 
A descript ive study of the d i f ferent electrophoretic patterns on 
agarose of human serum very low density l ipoproteins, Clin.Chem., 
24 (1978) 1439. 
18. Demacker, P.N.M., Van Sommeren-Zondag, D.F., Stalenhoef, A.F., 
Stuyt, P.M. and Van 't Laar, A. Ultracentrifugation in swinging 
bucket and determination of high-density lipoprotein subfractions 
HDL2 and HDL3, Clin.Chem., 29 (1983) 656. 
19. Demacker, P.N.M., Hijmans, A.G.M., Vos-Janssen, H.E., Van 't Laar, A. 
and Jansen, A.P. A study of the use of polyethylene glycol in 
estimating cholesterol in high-density lipoprotein, Clin.Chem., 26 
(1980) 1780. 
20. Bessey, O.A., Lowry, O.H. and Broek, M.J. A method for the rapid 
determination of alkaline phosphatase with five cubic millimeters 
of serum, J.Biol.Chem., 164 (1964) 321. 
21. Henry, R.J., Chiamori, N.. Golub, O.J. and Beekman, S. Revised 
spectrophotometriс methods for the determination of glutamic-
oxalacetic transaminase, glutamic-pyruvic transaminase and lactic 
acid dehydrogenase, Amer.J.Clin.Path., 34 (1960) 381. 
22. Szasz, G. A kinetic photometric method for serum γ-glutamyl 
transpeptidase, Clin.Chem., 15 (1969) 124. 
23. Skalhegg, B.A. On the 3a-hydroxysteroid dehydrogenase from 
Pseudomonas testosteron, Europ.J.Biochem., 46 (1974) 117. 
24. La Russo, N.F., Szczepanik, P.A. and Hofman, A.F. Effect of 
deoxycholic acid ingestion on bile acid metabolism and biliary 
41 
l i p i d secretion in normal subjects, Gastroenterology, 72 (1977) 132. 
25. Kloeze, J . , Houtsmuller, U.N.T. and Vies, R.O. Influence of dietary 
f a t mixtures on p l a t e l e t adhesiveness, atherosclerosis and plasma 
cholesterol content in rabbits. J.Atheroscler.Res., 9 (1969) 319. 
26. K i ta , T., Brown, M.S., Bilheimer, D.W. and Goldstein, J.L. Delayed 
clearance of very low density and intermediate density l ipoproteins 
with enhanced conversion to low density l ipoprote in in WHHL rabbi ts, 
Proc.Natl.Acad.Sci. (USA), 79 (1982) 5693. 
27. Pittman, R.C., Carew, Т.Е., A t t i e , A.D., Witztum, J .L. , Watanabe, Y. 
and Steinberg, D. Receptor-dependent and receptor-independent 
degradation of low density l ipoprotein in normal rabbits and in 
receptor-deficient mutant rabbi t , J.Biol.Chem., 257 (1982) 7994. 
28. Goldstein, J .L. , Sobhani, M.K. and Faust, R.R. Heterozygous 
f a m i l i a l hypercholesterolemia - Failure of normal a l l e l e to 
compensate for mutant a l l e l e at a regulated genetic locus, Cell 9 
(1976) 195. 
29. Ahlberg, J . , Angelin, 3 . , Einarsson, K., Hellström, К. and Leyd, B. 
B i l i a r y l i p i d composition in normo and hyperlipoproteinemia, 
Gastroenterology, 79 (1980) 90. 
30. Andersen, E., Hellström, К. and Vessby, B. Bi le acid k i n e t i c s , 
steroid balance and b i l i a r y l i p i d s in hyperlipoproteinemia type I I I , 
Atherosclerosis, 39 (1981) 191. 
42 
Chapter IV 
A COMPARATIVE STUDY ON SERUM LIPIDS AND ATHEROSCLEROTIC PLAQUE 
FORMATION IN DIET-INDUCED AND FAMILIAL HYPERCHOLESTEROLEMIA IN 
RABBITS, AND THE EFFECT OF PARTIAL ILEAL BYPASS 
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ABSTRACT Aim of the present study was to compare an alimentary and a 
hereditary rabbit model for hypercholesterolemia. Serum l i p i d s , 
serum l ipoproteins and d is t r ibu t ion and prevention of athero-
sc lerot ic plaque formation were studied in (1%) cholesterol-fed 
NZW rabbits and both heterozygous and homozygous WHHL rabbi ts . 
Cholesterol-fed NZW rabbits showed a hypercholesterolemia without 
hypertriglyceridemia, caused by accumulation of a spectrum of 
cholesterol ester-r ich ß-migrating l ipoproteins with a re la t i ve l y 
low density. The WHHL rabbits displayed both a hypercholesterol-
emia with an elevation of LDL, and a hypertriglyceridemia. The 
hypertriglyceridemia in the WHHL homozygotes was due to accumu-
la t ion of VLDL remnants and in the heterozygotes to a s l i gh t r ise 
in normal pre-0 VLDL. Despite the pronounced quant i tat ive and 
qual i ta t ive differences in l ipoprote ins, the location and 
extent of atherosclerotic plaques which had developed a f ter 
13 weeks cholesterol-rich diet in NZW rabbits and in 10 months 
old homozygous WHHL rabbi ts , was quite s imi lar . Part ia l i l ea l 
bypass surgery lowered serum cholesterol in a l l three groups and 
also prevented atherogenes!s. 
IV.2 INTRODUCTION 
Research into development and prevention of atherosclerosis has 
produced a number of animal models for hypercholesterolemia. Rabbits with 
an exogenous hypercholesterolemia have been widely used to th is extent 
(1-5). The addition of cholesterol to rabbit food results in a rapid and 
quite spectacular increase in serum cholesterol leve ls , which ul t imately 
leads to plaque formation in the vessel wall and to l i p i d deposition in 
other viscera (2) . The Watanabe heri table hyperlipidemic (WHHL) rabbit has 
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recently been introduced as a particularly appropriate model for homozygous 
familial hypercholesterolemia. The rabbits show structural deformities of 
LDL-receptors which appear similar to those encountered in the human 
disease (6,7). All animals display spontaneous aortic atherosclerosis at 
the age of 5 months (6). A comparison of exogenous and endogenous forms 
of hypercholesterolemia in the same animal species might yield valuable 
information concerning the role of the lipoprotein pattern on the mode of 
plaque formation. So far, the Carneau pigeon has been the only animal model 
available for endogenous hypercholesterolemia and spontaneous athero-
sclerosis. Striking differences in the localisation of atherosclerotic 
plaques were observed (8), comparing Carneau pigeons with cholesterol fed 
rabbits, which were thought to originate from the different forms of 
atherosclerosis (endogenous vs. exogenous). Equal atherosclerosis has 
been found in different types of exogenous hypercholesterolernie rabbits (4). 
In the present paper we have related the quantitative and qualitative 
aspects of serum lipids and serum lipoproteins to the place and extent of 
atherosclerotic plaques in cholesterol fed and WHHL rabbits. The effect of 
construction of a partial ileal bypass (PIB) as a preventive measure 
against atherosclerosis was also investigated. 
IV.3 MATERIALS AND METHODS 
Three experimental groups were investigated. Group 1, diet induced 
hyperlipidemia, consisted of 24 male New Zealand White (NZW) rabbits which 
underwent either a sham (n=7) or a PIB (n=17) operation at the age of 
4 months. From 3 weeks post-operatively onwards they were fed a commercial 
diet (LK04, Hope Farms, Woerden, The Netherlands) enriched with 1% 
cholesterol for 13 weeks, after which period they were sacrified. Group 2, 
endogenous hypercholesterolemia, consisted of 11 homozygous male WHHL 
rabbits which underwent either a sham (n=6) or a PIB (n=5) operation at the 
age of 13 weeks and which were sacrified 30 weeks after operation. These 
animals were bred by crossing and back-crossing between NZW rabbits and WHHL 
rabbits (a generous gift from Dr.Y.Watanabe). The animals were considered 
heterozygous or homozygous if their serum cholesterol was lower or higher 
than 6.0 mmol/1, respectively. We found that the serum cholesterol values of 
100 offspring at the age of 12 weeks showed a bimolar distribution with 
a cut-off limit between both groups at 6.0 mmol/1 (results to be published). 
Finally group 3 consisted of 23 male heterozygous WHHL rabbits which 
underwent either a sham (n=12) or a PIB (n=ll) operation at the age of 
13 weeks and which were sacrified 27 weeks after operation. All WHHL 
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rabbits were fed a commercial diet without cholesterol. 
Operations were performed under general anesthesia, induced by an 
oxygen-nitrous oxide-fluothane mixture. During the sham operation a 
laparotomy was performed, followed by measuring the total length of the 
small bowel. The PIB operation was essentially the same as described by 
Buchwald (9). The distal third of the small bowel was bypassed by an 
end-to-side anastomosis between ileum and ascending colon, immediately 
above the ileocoecal valve. PIB animals were given an intramuscular 
Vitamin B12 injection every 8 weeks. Animals were housed individually and 
fed ad libitum. 
Blood samples were collected after an overnight fast. Cholesterol in 
serum was measured by the CHOD-PAP method (10,11) and triglycerides by an 
enzymatic method (12). Lipoproteins were separated by density gradient 
ultracentrifugation in a swinging bucket rotor (13) and isolated on the 
basis of the coloured band distribution. Agarose gel electrophoresis was 
performed as described previously (14). Protein was measured by the Lowry 
method (15) and phospholipids were measured enzymatically using a 
commercial kit (WAKO, Highaski-Ku, Osaka, Japan). 
At sacri fiction the aortas with carotid and iliac branches and the 
truncus pulmonalis were dissected. The aortas were divided into the 
following segments: the aortic arch, the part which ends immediately 
after the left subclavian artery branching, the thoracic aorta which runs 
to the branching of the mesenteric artery and the abdominal aorta which 
ends at the bifurcation. The vessels were opened longitudinally, fixed 
in 10% formaline, coloured with Sudan IV, washed in 70% ethanol and water 
and kept in 10% formaline (16). Subsequently, they were placed between 
glass plates and photographed. The film was projected enlarged on a table 
with a coordinate system. The area of the segment was encircled and the 
coordinates of the perimeter were taken. A computer programme calculated 
the surface of the segment from these coordinates. Plaque surface was 
measured in a similar manner. The results are given as means with SD. 
Differences between groups were evaluated statistically by means of the 
Wilcoxon test, for unpaired observations. 
IV.4 RESULTS 
1. Comparison of Serum Cholesterol, Triglyderides and Lipoproteins in the 
Various Hypercholesterolemic Models 
Serum cholesterol and triglycerides in 4 months old NZW rabbits 
(group 1) averaged 1.1 + 0.6 mmol/l and 0.45 + 0.18 mmol/1, respectively 
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FIGURE 1 
Effects of PIB and sham operation on serum cholesterol in cholesterol-fed 
NZW rabbits (A), homozygous WHHL rabbits (B) and heterozygous WHHL rabbits 
(C). 
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(n=24). Addition of 1% cholesterol to the diet of sham-operated rabbits 
resulted in an enormous rise in serum cholesterol (Figure 1A). Values 
after 3 and 7 weeks on this diet averaged 25.3 + 4.2 and 39.0 + 12.2 
mmol/1, respectively. Cholesterol was distributed nearly equally between 
VLDL (density < 1.006) and LDL fractions (Table I). During the construction 
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of the density gradient, a large amount of lipoproteins from serum of NZW 
cholesterol-fed rabbits spontaneously floated to the top of the tube, 
indicating that the density of these lipoproteins, recovered after ultra-
centri fugati on in the VLDL fraction, was very low. After centri fugati on 
the gradient showed, beside the lipoproteins at the top of the tube, also 
other lipoproteins with a rather heterogenous density ranging from 1.006 
to 1.040 g/ml with the highest intensity around 1.019 g/ml. HDL-cholesterol 
also increased after cholesterol feeding (0.5 + 0.2 mmol/l), while serum 
triglycerides were unaffected. 
In the homozygous WHHL rabbits (group 2) mean serum cholesterol at an 
age of 12 weeks was 15.3 + 3.3 mmol/l. This level remained essentially 
unchanged with increasing age (data not shown). Sham operation did not 
affect serum cholesterol: average serum cholesterol after operation was 
16.3 + 3.2 (n=6) mmol/l. In these rabbits approximately one-third of the 
serum cholesterol was present as VLDL-cholestero! and was recovered at the 
top of the density gradient. The remainder of the serum cholesterol was 
recovered in a sharply confined LDL (1.024 < d < 1.038 g/ml; Table I). No 
lipoproteins with an intermediate density of approximately d = 1.019 were 
visible. Homozygous WHHL rabbits showed a marked hypertriglyceridemia if 
TABLE I 
Concentration of Total Cholesterol and Triglycerides in Serum and 
Distr ibut ion of Cholesterol over the Lipoprotein Fractions in the Three 
Groups of Sham-Operated Rabbits. Values are Means + SD, Expressed in 
mmol/l. 
serum VLDL* LDL** HDL serum 
cholesterol cholesterol cholesterol cholesterol t r ig lycer ides 
NZW rabbits 
chol .-fed 2 5 . 3 + 4 . 2 1 0 . 5 + 2 . 1 1 1 . 9 + 3 . 2 1 . 0 + 0 . 2 0 . 6 + 0 . 6 
(n=7) -
WHHL r a b b i t s 
homozygous 1 6 . 3 + 6 . 2 4 . 4 + 2 . 3 1 0 . 1 + 3 . 5 0 . 2 + 0 . 1 6 . 3 + 2 . 5 
(n=6) -
WHHL rabbits 
heterozygous 2.1 + 0.4 0.2 + 0.1 1.3 + 0.3 0.4 + 0.1 1.3 + 0.4 
(n=7) -
* d < 1.006 g/ml 
** 1.006 < d < 1.063 g/ml 
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compared to cholesterol-fed and normally fed NZW rabbits. At an age of 
12 weeks, the heterozygous WHHL rabbits of group 3 displayed an average 
serum cholesterol level of 2.6 + 1.0 mmol/l, which value is significantly 
(p < 0.01) higher than that observed in NZW rabbits of the same age 
(1.3 + 0.3 mmol/l, n=15). Most of the cholesterol was present in the LDL 
fraction (Table I). These rabbits also showed a relative hypertriglyceri-
demia if compared to NZW rabbits of the same age, which displayed serum 
triglyceride concentrations of 0.48 + 0.13 mmol/l (n=7). 
Marked differences existed between the chemical composition of the 
VLDL fractions from the three experimental groups (Table II). In cholesterol 
fed NZW rabbits this fraction was low in protein and triglycerides, while 
the ratio cholesterol esters-unesterified cholesterol was very high (7:1). 
The protein content in both homozygous and heterozygous WHHL rabbits was 
similar. The level of triglycerides in heterozygotes and homozygotes was 
increased, comprising 42% and 18% of dry weight, respectively. This 
phenomenon was accompanied by a decrease of the cholesterol esters. The 
cholesterol ester-unesterified cholesterol ratio in homozygotes was lower 
(5:1) than in NZW rabbits but higher than in heterozygotes (3:1). 
Agarose gel electrophoresis of total serum lipoproteins from 
cholestero!-fed NZW rabbits showed an abundance of material in the beta 
region (Figure 2, 1A). The same pattern was found after electrophoresis 
TABLE II 
Chemical Composition of the VLDL (d < 1.006 g/ml) Fraction in Serum from 
the Three Groups of Hypercholesterolernie Rabbits. Values are Means + SD, 
Expressed as Percentage Dry Weight. 
unesteri f ied cholesterol 
protein cholesterol ester t r ig lycer ides phospholipids 
NZW rabbits 
chol . - fed 4 . 9 + 0 . 5 1 0 . 7 + 0 . 1 7 6 . 8 + 0 . 9 1 . 0 + 0 . 2 6 . 6 + 0 . 1 
(n=3) -
WHHL rabbits 
homozygous 11.3 + 0.7 9.7 + 1.3 52.4 + 5.8 18.0 + 5.9 8.6 + 0.5 
(n=2) _ _ _ _ _ 
WHHL rabbits 
heterozygous 12.0 + 1.8 7.5 + 2.2 22.0 + 6.1 42.4 + 4.3 16.0 + 2.4 
(n=3) _ _ _ _ _ 
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of the VLDL fraction (Figure 2, IB). Total serum lipoproteins of homo-
zygous WHHL rabbits (Figure 2, 2A) consisted of one intensily stained 
band with a mobility slightly faster than the band with ß-mobility in 
the serum of the cholesterol-fed NZW rabbits. In addition, a minor extra 
band was usually visible moving ahead of this intensily stained band. 
The VLDL fraction contained this fast moving band, if present in whole 
serum, and also these lipoproteins of the intensily stained band with 
the greatest mobility (Figure 2, 2B). The lipoproteins with slower 
mobility were recovered in the d < 1.006 fraction. Thus, if compared 
to the cholesterol-fed NZW rabbits, the bulk of lipoproteins in the 
homozygous WHHL rabbits has a faster electrophoretic mobility and a 
higher density. 
FIGURE 2 
Agarose gel electrophoresis of whole serum and the VLDL fraction from 
rabbits with different forms of hypercholesterolemia. Whole serum (A) 
and VLDL fractions (B) are compared for cholesterol-fed NZW rabbits (1) 
and homozygous (2) and heterozygous (3) WHHL rabbits. The 3 and pre-B 
positions of normal human serum are indicated. Fractions 1 and 2 were 
analyzed on the same plate, but fraction 3 was run in a different 
experiment. The VLDL fraction 3B could only be analyzed after 
concentration. 
pre 
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The lipoproteins of heterozygous WHHL rabbits mainly displayed a 
normally migrating ß-band in whole serum. The concentrated d < 1.006 
fraction contained a normally moving pre-0 band with some slower moving 
lipoproteins (Figure 2, ЗА and 3B, respectively). 
2. Effects of PIB on Serum Cholesterol and Triglycerides in the Various 
Hypercholesterolemic Models 
In cholesterol-fed NZW rabbits PIB effectively prevented the large 
rise in serum cholesterol observed in sham-operated animals (Figure 1A). 
After 7 and 13 weeks of cholesterol feeding the concentrations of serum 
cholesterol were 3.8 + 4.6 and 1.4 + 1.5 (n=17) mmol/1, respectively. 
In homozygous WHHL rabbits PIB resulted in a rapid and sustained 
decrease of serum cholesterol (Figure IB), but the concentrations 
remained elevated if compared to those observed in NZW rabbits on a normal 
diet. 
Heterozygous WHHL rabbits showed a spontaneous decrease in serum 
cholesterol with age (Figure 1С). However, PIB resulted in an additional 
decrease: average concentrations remained significantly below those 
measured in the sham-operated controls, except for the values obtained 
9 and 18 weeks after operation. PIB did not result in significant changes 
in serum triglycerides in any of the three experimental groups. 
3. Comparison of Atherosclerotic Plaques Generated in the Various 
Hypercholesterolemic Models 
Figure 3 shows typical examples of plaque-pattern in both a 
7-months old sham-operated NZW rabbit, consuming a 1% cholesterol diet 
from 13 weeks before sacrifice, and a homozygous WHHL rabbit sacri fi ed 
at an age of 10 months. 
The distribution of the plaques over the different aorta segments 
appeared similar in the sham-operated cholesterol-fed and WHHL rabbits 
(Table III). In both groups of rabbits the more peripheral part of the 
aorta contained less plaques. PIB appeared to prevent the formation of 
atherosclerotic lesions very effectively (Table III). In addition, nine 
months-old WHHL heterozygotes had not formed any macroscopically or 
microscopically significant aortic plaques. The plaques generated in both 
cholesterol-fed NZW rabbits and homozygous HHHL rabbits were microscopi­
cally identical, as envisaged after Sudan-staining. Underneath the endo­
thelial layer intracellular lipid accumulation occurred with occasional 
suppression on the media; the intima always remained intact. Occasionally 
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some calcified depositions were observed. Accumulation of foam cells was 
present in the corpus ciliare and the sclerae of both sham-operated groups. 
In neither of the models did hypercholesterolemia lead to formation of 
plaques in coronary vessels. 
FIGURE 3 
Plaque formation in aortas from cholesterol-fed NZW rabbits and 
homozygous WHHL rabbits. Typical examples of plaque formation in 
cholesterol-fed NZW rabbits (left) after sham operation and in homozygous 
WHHL rabbits after sham operation (right). Both aortic arch and thoracic 
aorta are depicted. 
TABLE I I I 
Area of Plaques as Percentage of Total Vessel Area 
aor t ic thoracic abdominal arteriae 
arch aorta aorta i l iacae 
NZW rabbits 
cholesterol-fed: 
sham-operated 
(n=7) 
PIB (n=17) 
Ρ 
WHHL rabbits 
homozygous : 
sham-operated 
(n=6) 
PIB (n=5) 
P* 
42 + 23 
3 + 5 
< 0.01 
54 + 21 
7 + 9 
< 0.01 
19 + 17 
0 + 1 
< 0.01 
9 + 4 
1 + 1 
< 0.01 
11 + 11 
0 + 1 
< 0.01 
6 + 3 
0 
< 0.01 
7 + 9 
0 + 1 
< 0.01 
0 
0 
-
p-value calculated by means of a Wilcoxon two-sided unpaired test 
IV.5 DISCUSSION 
The present work extends to a paired study observations made by 
others in the separate rabbit models (1-6, 17, 18) and confirms that there 
exist striking differences in serum lipids and lipoproteins between the 
three experimental groups of rabbits. 
Feeding cholesterol to NZW rabbits produces a spectrum of lipoproteins 
on average rich in cholesterol-esters but poor in both triglycerides and 
proteins, with ß-mobility upon electrophoresis in agarose and with a 
relatively low density. The HDL fraction was relatively enriched in 
cholesterol, which phenomenon is probably caused by an increase in HDL 
; i 9 ) . 
Both groups of WHHL rabbi ts , but not the cholesterol-fed NZW rabb i ts , 
displayed a hypertriglyceridemia next to the hypercholesterolemia. The 
electrophoretic mobi l i ty of the d < 1.006 g/ml f ract ion from the WHHL 
homozygotes has been characterized as 3 (6) or as normal pre-$ (20). We 
observe an intermediate B-pre В mobi l i ty and the tr ig lycer ide-n'ch l i p o ­
proteins from the WHHL homozygotes display, in contrast to those from 
cholesterol-fed NZW rabbits (21), an electrophoretic pattern similar to 
that found in patients with type I I I hyperlipoproteinemia (group V p a t t e r n , 
14). The VLDL cholesterol/VLDL t r i g l y c e r i d e r a t i o in the d < 1.006 g/ml 
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fraction was higher in homozygotes than in heterozygotes, although not as 
high as in the cholesterol-fed NZW rabbits. Since normal pre-ß material 
is almost absent, an increased level of VLDL remnants (d < 1.006 g/ml) must 
be the cause for the hypertriglyceridemia in the WHHL homozygotes. In the 
heterozygotes hypertriglyceridemia is caused by a slight enhancement of 
VLDL with normal composition and mobility. 
It has been suggested that the degree of atherosclerosis is related 
to the intensity and duration of the hypercholesterolemia in cholesterol-
fed NZW rabbits (1). In our experiment, the hypercholesterolemia in 
cholesterol-fed rabbits was on average 2-3 fold higher than in homozygous 
WHHL rabbits. However, hypercholesterolemia in WHHL rabbits was present 
for 43 weeks, from birth to sacrifice, while in NZW rabbits it only lasted 
for 13 weeks, i.e. approximately 1/3 of the duration in WHHL rabbits. 
Remarkably, the end result, in terms of atherosclerotic plaque formation, 
appeared quite similar in both forms of hypercholesterolemia. The histology 
of the plaques and the absence of coronary pathology indicates a relatively 
young stage of atherosclerosis. Both models show coronary disorders in a 
more advanced stage (2,18). We found the plaques to be preferentially 
located in the aortic arch and at the origins of the thoracic aorta 
(Table III). The typical V-configuration (Figure 3) of these lesions in 
both forms of hypercholesterolemia indicates that hemodynamic factors, and 
not the type of hypercholesterolemia, are primarily responsible for their 
localisation. The Carneau pigeon does not develop atherosclerotic plaques 
in the aortic arch but rather in the distal aorta (22). This has been 
taken as evidence that exogenous hypercholesterolemia (as in cholesterol-
fed rabbits) and endogenous hypercholesterolemia induce different patterns 
of atherosclerosis (8). Our results do not support this. Probably, the 
species studied is more important in this respect. Macroscopically, we 
observed no differences in plaque between cholesterol-fed NZW rabbits and 
WHHL rabbits. In contrast, Buja et al. (18) observed the occurrence of 
arterial lesions of a pure foam cell type in cholesterol-fed rabbits, 
while WHHL rabbits displayed both foam cell type lesions and atheromatous 
plaques. This apparent discrepancy may possibly be explained by 
differences in diet regimen: 2% cholesterol over a 2-week period, 
compared to 1% cholesterol for 13 weeks in our study. The latter situation 
might be more closely related to the WHHL model. 
Rabbits which were bred from homozygous WHHL rabbits and NZW rabbits 
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and which at an age of 12 weeks showed serum cholesterol levels lower than 
6 mmol/1, were designated heterozygote. While average serum cholesterol 
levels during their early life span were significantly higher than in age-
matched NZW rabbits, this difference did disappear with time (results not 
shown). Therefore, it is hardly surprising that these animals had not yet 
developed any plaques at an age of 40 weeks. 
Partial ileal bypass has been shown to return serum cholesterol levels 
to normal in cholesterol-fed rabbits (23), mainly by preventing cholesterol 
resorption (24). Our results show that PIB prior to cholesterol feeding 
prevents both a subsequent rise in serum cholesterol (Figure 1) and the 
formation of atherosclerotic plaques (Table III). In the present experiment 
PIB induced a sharp and persistent decrease in serum cholesterol in all 
homozygous WHHL rabbits. While the resulting levels remained significantly 
elevated as compared to NZW controls, this lowering of serum cholesterol 
was sufficient to almost completely prevent plaque formation (Table III). 
Thus, PIB not only lowers serum cholesterol in different forms of rabbit 
hypercholesterolemia, but it also protects against atherosclerosis in both 
models. 
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Chapter V 
BILE ACID DRAINAGE BY PARTIAL SMALL BOWEL BYPASS OR CHOLESTYRAMINE: 
EFFECTS ON SERUM CHOLESTEROL IN WHHL RABBITS 
J.L.M. van Niekerk, Th. Hendriks and H.H.M, de Boer 
Eur.Surg.Res., in press 
V.l Abstract 
The effects of bile acid drainage on serum cholesterol levels have 
been investigated in WHHL rabbits, a unique model for homozygous 
familial hypercholesterolemia. 
Cholestyramine medication lowered serum cholesterol concentrations 
with 38%, while a 33% and a 50% small bowel bypass resulted in a 
decrease of 56 and 48%, respectively. Cholestyramine treatment after 
either bypass induced a minor additional fall in serum cholesterol. Ileal 
bypass and ileal resection were equally effective in reducing serum 
cholesterol. 
These results indicate the necessity for further investigation into 
the potential of bile acid drainage as a therapy in homozygous familial 
hypercholesterolemia. 
V.2 Introduction 
The primary aim of treatment of patients with familial hyper-
cholesterolemia is lowering of serum cholesterol. One way to induce a 
reduction in serum cholesterol is the interruption of the enterohepatic 
cycle of bile acids, either by ingestion of bile acid-binding resins, 
e.g. cholestyramine, or by partial ileal bypass (PIB) surgery. 
Surgical intervention by means of PIB has been accepted as a 
possible means of treatment of patients with heterozygous familial 
hypercholesterolemia. The operation may be expected to substantially 
lower the serum cholesterol levels in this type of patient (4). However, 
in patients with the homozygous type of familial hypercholesterolemia, 
the lipid-lowering potential of the operation is still in doubt. In 
three out of seven patients subjected so far to PIB for this type of 
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disease, serum cholesterol levels were not changed by operation (1,4,6,8, 
10). 
Animal models, particularly rabbits made hypercholesterolemic by a 
cholesterol-rich diet, are a valuable tool to investigate the mechanisms 
of bile acid drainage and its effects on lipoprotein metabolism and 
atherosclerosis (9,12,14,17), but their relation to human familial 
hypercholesterolemia remains questionable. Recently, a unique animal 
model for homozygous human familial hypercholesterolemia has become 
available in the form of the Watanabe Heritable Hyperlipidemic (WHHL) 
rabbit, which animal displays spontaneous hypercholesterolemia and 
atherosclerosis (16). 
The present paper compares the serum cholesterol-lowering effects 
of small bowel bypass, small bowel resection and cholestyramine treatment 
in the WHHL rabbit. 
V.3 Methods 
A strain of WHHL rabbits was bred by crossing and back-crossing 
between WHHL males (kindly donated by dr. Y. Watanabe) and New Zealand 
White (NZW) females. Homozygous female rabbits aged between 5 and 7 
months, and varying in weight between 1900 and 2950 g, were used in this 
study. The animals were divided into 3 groups. 
Group 1 (n=5) received a 33% small bowel bypass, followed by a 
cholestyramine-containing diet for 8 weeks, starting 6 weeks after 
operation. Group 2 (n=5) was treated with cholestyramine for 6 weeks. 
Thereafter, a 50% bypass was constructed and the cholestyramine treat-
ment was repeated from 6 weeks post-operatively onwards. Group 3 (n=6) 
received a 33% bypass. After 6 weeks the bypassed segment was resected. 
The animals were caged individually and fed ad libitum with a chow 
diet (LK04, Hope Farms, Woerden, The Netherlands). During the choles-
tyramine studies the animals were fed a daily dose of 3 g cholestyramine 
(Questran, a gift from Bristol-Myers BV, The Netherlands), which had 
been added to the normal food mixture before pelleting. Blood samples 
were collected after an overnight fast and serum cholesterol was 
measured by the CH0D-PAP method (11,15). 
Operations were performed under general anesthesia, induced by an 
oxygen-nitrous oxide-fluothane mixture. The entire small bowel was 
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brought out the abdominal cavity through a midline incision. The bypass 
point opposite the appendical tip, recommended by Buchwald (2), was 
marked (Fig. 1). The small bowel was stretched fully and measured twice 
along the mesenteric side with a smooth silk thread. The distal 33% 
or 50% of the small bowel was then bypassed by constructing a side-to-
side anastomosis between ileum and ascending colon with a single layer 
of interrupted vicryl 5x0 stitches. The blind loop was closed by a 
ligature. Excision of the bypassed segment (group 3) was performed by 
ligation of the mesenteric vessel branches and inverting the resection 
ends. All animals received antibiotics pre-operatively and 2 days post-
operatively and a vitamin B12 injection every 8 weeks after operation. 
Results are expressed as mean + SD. The effects of various treat-
ments on serum cholesterol levels were evaluated statistically by 
comparing values obtained during treatment with the values obtained in 
the previous control period using a non-parametric test (I) based on the 
average of Wilcoxon two sample statistics computed for each rabbit 
separately. For this test, weeks of treatment and control period were 
selected where no significant common trend in the values could be 
established by means of Kendal's test for concordance (Friedman test). 
The effects of two different treatments, examined in the same group of 
rabbits, were compared by applying test I to values obtained for each 
effect by random combinations of a control value and a value in the 
treatment period in question (test II). The effects of two treatments, 
which had been investigated in different groups of rabbits, were 
compared by applying the Wilcoxon two sample test on differences of 
means obtained from values in the treatment and preceding control 
periods, with a similar restriction regarding common trend as mentioned 
for test I. 
V.4 Results 
In our experiments the point of small bowel ligation, and thus the 
length of the bypass, has been determined after measuring the total 
length of the small bowel. Two consecutive measurements of small bowel 
length resulted in similar values, the difference between measurements 
averaging only 3% of total length. Construction of a bypass with respect 
to an anatomical reference point, as suggested by Buchwald (2), would 
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have resulted in a bypass considerably shorter than desired. It was 
calculated in 8 rabbits that ligation of the ileum opposite the 
appendical tip would have yielded a bypass averaging only 24% of total 
small bowel length. This fact is further illustrated in Fig. 1, which 
shows the points of ligation for the various bypasses. 
FIGURE 1 
Position of ligation of the small bowel in construction of ileal bypass. 
В denotes the bypass point if the appendical tip is used as anatomical 
reference point. Calculation of the position of the bypass point after 
measuring total small bowel length yields the sites indicated by 
1/3 and 1/2 for a 33% and a 50% bypass, respectively. 
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All rabbits lost weight after operation. Six weeks after a 33% 
bypass animals had regained their pre-operative weight. Average weight 
6 weeks after a 50% bypass was still lowered, but the difference 
between the two types of operations was not significant. 
A 33% bypass considerably reduced serum cholesterol levels (Fig. 2B, 
C). Average decrease was 9.1 + 2.1 mmol/1, amounting to 56% of the pre-
operative value. Subsequent cholestyramine treatment resulted in a 
further, significant (p < 0.001), decrease which averaged 1.6 + 1.1 
mmol/1. A 50% bypass induced a lowering of serum cholesterol with 
6.9 + 3.4 mmol/1 (Fig. 2A). This reduction, which comprised 48% of the 
pre-operative level, was not significantly different from that observed 
after a 33% bypass. However, while cholestyramine treatment on the 
average resulted in a further reduction, with 0.9 + 2.0 mmol/1, of 
serum cholesterol levels, this effect remained statistically non-
significant. 
The effect of cholestyramine treatment alone was investigated in 
non-operated rabbits (Fig. 2A). Clearly, cholestyramine showed a marked 
cholesterol-lowering potential in these animals with homozygous 
hereditary hypercholesterolemia. The mean reduction in serum cholesterol 
concentration was 6.0 + 1.5 mmol/l, which was not significantly different 
from the fall in cholesterol observed subsequently after a 50% bypass 
constructed in the same rabbits. 
Finally, it is shown in Fig. 2C that excision of the bypassed 
segment 6 weeks after a 33% bypass had no effect on the level of 
circulating cholesterol. 
V.5 Discussion 
It has been suggested, in order to construct a PIB in rabbits, to 
use the appendi cai tip as an anatomical reference point to determine the 
site of ligation of the ileum (2). Testing this procedure, we did find 
that it would have yielded quite a variation in bypass length and that 
the bypass never would have reached the required length of 33% of the 
total small bowel. This phenomenon is probably caused by the fact that 
the position of the point opposite the appendical tip depends on the 
way the mesentery is unfolded. In our experience, the only way to 
construct a bypass of reproducible length is by measuring the entire 
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FIGURE 2 
Effect of various bile acid draining procedures on serum cholesterol 
levels. Three different groups of rabbits were treated with, respectively, 
cholestyramine and subsequently a 50% small bowel bypass and cholesty­
ramine (A), a 33% small bowel bypass and cholestyramine (B), and a 33°» 
small bowel bypass followed by resection (C). Values are means + SD. 
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small bowel length and calculating the exact bypass point. 
Bile acid-binding resins, e.g. cholestyramine, are the most 
important class of drugs currently employed to lower serum cholesterol 
in human familial hypercholesterolemia (7). By preventing reabsorption 
they interrupt the enterohepatic cycle of bile acids, thus draining 
the liver of cholesterol and increasing receptor-mediated uptake of 
low density lipoproteins into the liver (5). PIB essentially has the 
same effect, shunting the intestinal segment where bile acids are 
preferentially resorbed. In heterozygous familial hypercholesterolemia 
in man, PIB is more effective than cholestyramine in lowering serum 
cholesterol (10,13). In our animal experiment, cholestyramine treatment 
alone significantly reduced serum cholesterol (Fig. 2A). Also, both 
a 33% and a 50% small bowel bypass resulted in an immediate and per-
sistent decrease of serum cholesterol levels (Fig. 2A,B). There was no 
significant difference in the size of the effect induced by cholestyramine 
or 50% bypass in the same rabbits, neither between a 33% and a 50% 
bypass in different groups of rabbits. We have also investigated if 
cholestyramine, given after construction of the bypass, would further 
lower serum cholesterol. While mean serum cholesterol levels during 
cholestyramine treatment were actually lowered, both after 33% (from 
7.3 + 0.7 to 6.1 + 1.0 rrmol/l) and 50% (from 6.9 + 0.9 to 5.9 + 1.1 
mmol/1) bypass, this effect was only signficant in the 33% bypass group. 
However, it seems premature to conclude from the data presently 
available that bile acid drainage is more effective after 50% bypass 
than after 33% bypass. The number of WHHL rabbits available for 
experimentation has been rather small and a direct quantitation of the 
relative effects of the various treatments seems unjustified at this 
stage. So far, it can only be stated unequivocally that both 
cholestyramine treatment and PIB lower serum cholesterol in WHHL rabbits. 
It has been reported that in normo-cholesterolemic rabbits PIB 
results in twice the reduction in circulating cholesterol as compared to 
the reduction observed after excision of a similar intestinal segment (3). 
However, we did not observe any change in serum cholesterol if a PIB 
was followed by excision of the bypassed segment (Fig. 2C). 
It should be emphasized that, though the bile acid draining 
procedures described certainly lower serum cholesterol to a considerable 
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degree, the remaining levels are still strongly enhanced as compared to 
those observed in normal NZW rabbits (which range between 0.8 and 2.0 
mmol/1). Still, the present experiments with this new and unique animal 
model for homozygous familial hypercholesterolemia appear to underline 
the possibilities of bile acid drainage as a mode of treatment in 
familial hypercholesterolemia. Further investigation into the effects 
of bile acid drainage on lipoprotein metabolism, particularly receptor-
mediated uptake of low density lipoproteins, seems certainly warranted. 
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Chapter VI 
THE LIPID-LOWERING EFFECTS OF 3-HYDROXY-3-METHYLGLUTARIC 
ACID AND BILE ACID DRAINAGE IN WHHL RABBITS 
J.L.M. van Niekerk, Th. Hendriks, J.Α. Gevers Leuven and H.H.M, de Boer 
Submitted 
VI.l Summary 
1. The ef fect of 3-hydroxy-3-methylglutaric acid (HMG) on serum 
cholesterol levels was investigated in Watanabe heri table hyper-
lipidemic (WHHL) r a b b i t s . 
2. Oral administration of HMG resulted in a reduction of serum cholesterol 
with 39%. 
3. Bi le acid drainage, by means of ei ther cholestyramine medication or 
p a r t i a l i l e a l bypass (PIB) surgery, also led to s i g n i f i c a n t reductions 
in c i r c u l a t i n g cholestero l , with 35 and 59% respectively. 
4. A combination of cholestyramine and HMG was no more ef fect ive than 
separate administration of e i ther compound. 
5. Intra-peritoneal i n j e c t i o n of HMG a f t e r PIB surgery further reduced 
serum cholesterol by 35%. 
6. The working mechanism of these l ip id- lower ing therapies in WHHL 
rabbits is discussed in re lat ion with recent l i t e r a t u r e . 
7. The s ign i f icant reductions in c i r c u l a t i n g cholesterol induced by 
HMG warrant further invest igat ion into the use of t h i s compound in 
the management of f a m i l i a l hypercholesterolemia. 
VI.2 Introduction 
Among the r isk factors f o r atherosclerotic cardiovascular disease, 
hypercholesterolemia is thought to be the single most important. 
Consequently, therapy in f a m i l i a l hypercholesterolemia aims to induce a 
maximal lowering of serum cholesterol. 
While diet and drug treatment may be s u f f i c i e n t in groups of 
patients with the heterozygous form of the disease, homozygous f a m i l i a l 
hypercholesterolemia remains a very d i f f i c u l t condition to t reat and has 
f a i l e d to respond adequately to a variety of drug regimen (1,2). 
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The search for more e f f i c i e n t l ip id- lower ing treatments in homo­
zygous f a m i l i a l hypercholesterolemia has been hampered by the fact that 
no suitable animal model for th is human disease has been avai lable. 
Recently, a unique experimental model has been developed in the form of 
the Watanabe heritable hyperlipidemic (WHHL) rabbit (3). Hypercholesterol­
emia in these animals shows great s i m i l a r i t y to the human form of the 
disease (4) . Experiments in our laboratory have revealed that surgical 
intervention in the form of a p a r t i a l i l e a l bypass (PIB) greatly reduces 
serum cholesterol levels in WHHL rabbits (5). 
Drugs which may possibly af fect serum cholesterol levels are b i l e 
acid resins, e.g. cholestyramine, and competitive inh ib i tors of 
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-
l i m i t i n g enzyme in cholesterol synthesis. The present paper reports on 
the l ip id- lower ing potential of one such i n h i b i t o r , 3-hydroxy-3-methyl-
glutar ic acid (HMG), in WHHL rabbits and compares i t s effects with those 
obtained by b i l e acid drainage. 
VI.3 Methods 
Homozygous female WHHL rabbits were bred by crossing and back-
crossing between New Zealand White (NZW) rabbits and WHHL rabbits (a 
generous gift from dr. Y. Watanabe). 
The animals were divided into two groups. Group I (n=5) first 
received HMG orally during б weeks; subsequently, a PIB was constructed 
and the animals were given HMG orally for 4 weeks, followed by HMG 
intra-peritoneally for 6 weeks. Group II (n=7) received cholestyramine 
for 6 weeks and thereafter a combination of cholestyramine and HMG (fed 
orally) also during 6 weeks. 
The rabbits were caged individually and fed ad libitum with a chow 
diet (LK04, Hope Farms, Woerden, The Netherlands). During the 
cholestyramine studies the animals were fed a daily dose of 3 g 
cholestyramine (Questran, a gift from Bristol-Myers BV, The Netherlands) 
which had been added to the normal food mixture before pelleting. HMG 
(Sigma Chemical Company, Saint Louis, USA) was dissolved in drinking 
water and given in a dose of 100 mg a day. During one experimental 
period a similar dose, dissolved in 5 ml physiological saline, was 
injected intra-peritoneally each day. The PIB operation was performed as 
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described elsewhere (5). 
Blood samples were collected after an overnight fast. Cholesterol 
in serum was measured by the CHOD-PAP method (6,7) and triglycerides 
by an enzymatic method (8). 
The effects of various treatments on serum cholesterol levels were 
evaluated statistically by comparing values obtained during treatment 
with the values obtained in the previous control period using a non 
parametric test (I) based on the average of Wilcoxon two sample 
statistics computed for each rabbit separately. For this test weeks of 
treatment and control periods were selected where no significant common 
trend in the values could be established by means of Kendal's test for 
concordance (Friedman test). The effects of two different treatments, 
examined in the same group of rabbits, were compared by applying test I 
to values obtained for each effect by random combinations of a control 
value and a value in the treatment period in question (test II). 
VI.4 Results 
Body weight in the 2 groups of animals remained unaffected by any 
of the treatments. An exception was group I during the first HMG regimen. 
Here, animals which were rather young and still growing at the start of 
the experiment, had gained some weight after the 6 weeks period 
(2400 + 80 g at 25 weeks vs. 2220 + 130 g at 19 weeks of age). The level 
of serum triglycerides also remained essentially unchanged over the 
experimental period in both groups. 
HMG, given orally over 6 weeks, lowered serum cholesterol 
considerably (Figure 1). Levels at 23 and 25 weeks were significantly 
(p=0.0003) reduced as compared to those obtained at 17 and 19 weeks. 
Average serum cholesterol during HMG treatment was lowered from 
18.7 + 0.9 (SD) to 11.5 + 2.8 mmol/1. The subsequent PIB procedure 
resulted in a sustained decrease of serum cholesterol. Comparison of 
any of the values measured before PIB, at 27, 29 or 31 weeks of age, 
with those obtained after PIB, at 33, 35, 37, 49 and 51 weeks, shows a 
very significant (p=0.0003) drop in serum cholesterol. Oral administration 
of HMG after surgery had no additional effect on circulating cholesterol, 
at least not within 4 weeks. However, if HMG was given intra-peritoneally, 
serum cholesterol levels decreased further. Concentrations measured at 
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FIGURE 1 
Effect of HMG medication on serum cholesterol levels in WHHL rabbits, 
before and after partial ileal bypass surgery. Results are depicted as 
means + SD (n=5). 
serum -cholesterol ( m mol /1 ) 
HMG-oral HMG-oral HMG-mtrapentoneal 
1 
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age in weeks 
59, 60 and 61 weeks were significantly lower than those observed in 
weeks 49 and 51 (pO.0001). Also, values obtained in weeks 56, 57 and 
58 were significantly (p=0.03) lower than those measured in weeks 49 and 
51. Average serum cholesterol during intra-peritoneal HMG administration 
was thus reduced from 6.9 + 0.7 (49 and 51 weeks) to 4.5 + 0.4 (59, 60 
and 61 weeks) mmol/1. 
Cholestyramine also reduced serum cholesterol in WHHL rabbits 
(Figure 2). Concentrations at 38 and 40 weeks were very significantly 
lower as compared to those measured at 32 and 34 weeks (p<0.0001). 
Average serum cholesterol at these measuring points was lowered from 
15.2+2.2 to 9.9+ 1.1 mmol/1. A combination of cholestyramine and 
HMG (oral) did result in a reduction of similar size and level of 
significance. Average serum cholesterol decreased from 14.8 + 2.6 
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(42 and 44 weeks) to 8.7 + 2.8 (48 and 50 weeks) mmol/l. S t a t i s t i c a l 
comparison of the effects induced by cholestyramine alone and by the 
simultaneous use of cholestyramine and HMG gives no support for any 
additive ef fect induced by HMG. 
FIGURE 2 
Effects of cholestyramine and of cholestyramine plus HMG (oral) 
medication on serum cholesterol levels in WHHL rabbits. Results are 
depicted as means + SD (n=7). 
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VI.5 Discussion 
The possibility of using HMG as a hypolipidemic drug in familial 
hypercholesterolemia has been investigated only incidentally. Lupien 
and coworkers have reported its protective action in diet-induced 
hypercholesterolemia in rabbits (9) and subsequently its use in 36 
heterozygous (10) and 1 homozygous (11) patient, where the drug appeared 
to be effective in lowering serum cholesterol, at the same time being 
well-tolerated and non-toxic. The present results, obtained with a new 
animal model for familial hypercholesterolemia, supply further evidence 
for the lipid-lowering potential of this compound. In all 5 rabbits of 
group I treated with HMG over a period of 6 weeks, serum cholesterol was 
lowered considerably. The average reduction was 39%, ranging from 24 to 
58%. In this respect, HMG appears to be equally effective in WHHL rabbits 
as compactin (12) which is a potent competitive inhibitor of HMG-CoA 
reductase. Compactin was recently shown to be effective in heterozygous 
patients (13,14). 
Cholestyramine also reduced serum cholesterol levels in WHHL 
rabbits (Figure 2). However, cholestyramine and HMG showed no additive 
effects in our experiment, while a combination of cholestyramine and 
compactin has been reported to work synergistically in dogs (15) and 
heterozygous patients (14). 
Earlier findings in our laboratory show that PIB strongly reduces 
serum cholesterol and inhibits atherogenesis in WHHL rabbits (5). Present 
results indicate that, if HMG was given orally after operation it 
remained uneffective, presumably because of impaired absorption from the 
gut. However, intra-peritoneal administration of HMG resulted in a 
further reduction of serum cholesterol. This underlines the potential 
powerful combination of bile acid drainage by means of PIB and choles-
terol synthesis inhibition as a therapy in familial hypercholesterolemia. 
This way, serum cholesterol levels in WHHL rabbits could be lowered from 
18.7 + 0.9 mmol/1 to 4.5 + 0.4 mmol/l, a reduction with 76%. 
Finally, our results may also have some implications for the animal 
model itself. Although Shimada et al. (16) have reported some low 
density lipoprotein (LDL)-receptor activity on fibroblasts derived from 
WHHL rabbits, the bulk of current evidence seems to indicate these 
animals to be receptor-negative, i.e. entirely without LDL-receptors (4). 
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Bile acid drainage, through PIB or cholestyramine treatment, supposedly 
causes serum levels of LDL-cholesterol to fall by means of ultimately 
increasing the number of LDL-receptors. Inhibitors of cholesterol 
synthesis, like compactin and HMG, are also thought to stimulate 
production of LDL receptors in the liver (17). Therefore, these therapi 
are not expected to be effective in receptor-negative familial hyper-
cholesterolemia homozygotes. The fact that HMG, cholestyramine and PIB 
significantly lower serum cholesterol levels in homozygous WHHL rabbits 
then must mean that either the animals are not completely receptor-
negative or that these therapies may lower serum cholesterol through 
some other mechanism. Further research seems necessary before definite 
conclusions about either possibility may be drawn. 
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Chapter VII 
NIFEDIPINE DOES NOT SUPPRESS ATHEROGENESIS IN WHHL RABBITS 
J.L.M. van Niekerk, Th. Hendriks, H.H.M, de Boer and Α. van 't Laar 
Submitted 
11.1 Abstract 
The effects of the calcium antagonist nifedipine on atherogenesis 
ere investigated in WHHL rabbits, a unique animal model for human 
amilial hypercholesterolemia. 
Nifedipine, in a daily dose of 40 mg, was fed orally to 9 rabbits 
ver a period of 26 weeks, resulting in serum concentrations between 
4 and 137 yg/dl. Rabbits were sacrificed in an age of 40 weeks and 
therosclerotic plaque formation in various aortic segments was 
uantified. Atherosclerosis was most pronounced in the aortic arch and 
he thoracic aorta, plaques covering, respectively, 59 + 17% and 
7 + 9% of total vessel area. These results are quite similar to those 
bserved in a control group, which received the same diet and no 
ifedipine and displayed lesions on 62 + 19% and 21 + 13% of total 
rea of aortic arch and thoracic aorta, respectively. 
It is concluded that nifedipine does not suppress atherogenesis 
η rabbits with hereditary hypercholesterolemia and that it may be 
remature to start clinical trials testing this agent as a mode of 
reatment of familial hypercholesterolemia. 
11.2 Introduction 
Ni fedi pi ne, dimethyl 1,4-di hydro-2,6-di methyl-4-(2-ni trophenyl ) -
,5-pyridinedicarboxylate, is a calcium antagonist widely used f o r 
reatment of angina pectoris on the basis of atherosclerosis (1). 
Recent experiments with cholesterol-fed rabbits suggest that 
i fedipine may also suppress atherogenesis without lowering serum 
holesterol (2) . Recently, the Watanabe heri table hyperlipidemic 
WHHL) rabbit has become avai lable, which animal displays the fol lowing 
h a r a c t e r i s t i c s : a genetical ly determined elevated cholesterol l e v e l , 
low density l ipoprotein receptor deficiency on f ibroblasts and 
hepatocytes and early atherosclerosis and xanthoma formation (3-5). As 
such, WHHL rabbits represent a unique animal model for human fami l ia l 
hypercholesterolemia. Therefore, i t seemed important to test whether 
nifedipine would also i n h i b i t atheroma formation in these animals. 
We report here that 6 months of nifedipine feeding does not af fect 
atherosclerotic plaque formation in WHHL rabbits. 
VII.3 Methods 
WHHL rabbits were bred by crossing and back-crossing between New 
Zealand White and WHHL rabbits (a generous g i f t from dr. Y. Watanabe). 
For t h i s study, only animals with serum cholesterol levels higher than 
250 mg/dl, measured at the age of 12 weeks, were used. From an age of 
14 weeks onwards, 10 rabbits (4 males and 6 females) were fed a diet 
enriched with ni fedipine and another group of animals was fed a simi lar 
chow d iet (LK04, Hope Farms, Woerden, The Netherlands) without added 
n i fedip ine. The experimental group received 40 mg nifedipine a day during 
б months. For th is purpose, nifedipine (a g i f t from Bayer Nederland BV) 
was mixed, in a r a t i o 40 mg/100 g, with the other food constituents 
before p e l l e t i n g . Both preparation of the food pel lets and subsequent 
storage took place under minimal i l luminat ion in order to prevent 
photo-degradation of n i fedip ine. A fresh batch of pel lets was produced 
every f o r t n i g h t . The rabbits in the experimental group did receive 
100 g nifedipine-enriched food a day; only af ter eating a l l these pel lets 
they were allowed addit ional nifedipine-free pel lets ad l i b i t u m . 
Nifedipine levels in serum were measured a f t e r 1 month diet by 
means of gas-chromatography (6). Blood samples were collected af ter an 
overnight f a s t . Cholesterol in serum was measured by the CH0D-PAP 
method (7,8) and t r i g l y c e r i d e s by an enzymatic method (9). VLDL-
cholesterol was determined in the d < 1.006 g/ml f ract ion isolated by 
u l t racentr i fugat ion (10) and HDL-cholesterol was determined in the 
d > 1.006 g/ml f r a c t i o n a f t e r precip i tat ing LDL with polyethylene 
glycol (11). Quantitation of atherosclerotic plaques has been described 
elsewhere (12). 
Results are expressed as mean + SD. Differences between and wi th in 
experimental and control groups were evaluated s t a t i s t i c a l l y by means o f , 
respectively, an unpaired and a paired two-sided student t - t e s t . 
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VII.4 Results 
Two rabbits, one each from the experimental and the control group, 
died spontaneously during the experiment. Thus, in both groups, all data 
concern 9 rabbits. 
Average weight at the start of the diet period was 1630 + 170 g for 
the control animals and 1730 + 150 g in the experimental group. At 
sacrifice, weights were 2580 + 190 g and 2520 + 120 g, respectively. 
The daily dose of 40 mg nifedipine resulted in serum nifedipine 
levels, measured after 1 month diet, between 74 and 137 ug/dl 
(mean + SD: 102 + 23). 
Serum cholesterol and triglyceride levels during the experimental 
period are represented in Figure 1. At 12 weeks of age, no significant 
difference existed, either in cholesterol or in triglycerides, between 
the animals in both groups. However, during the experimental period 
serum cholesterol levels in the control group were significantly higher 
on 3 out of 5 occasions. The average serum cholesterol concentration 
over the entire experimental period (as measured at 20, 26, 32 and 
38 weeks) in the control group was significantly elevated as compared to 
the mean value for the nifedipine group: 707 + 128 vs 576 + 108 mg/dl, 
TABLE 1 
Serum Lipoproteins 
control group (n=9) nifedipine group (n=9) 
Cholesterol 657 + 116* 509 + 141* 
VLDL-cholesterol 166 + 69 118 + 80 
LDL-chol estero! 484 + 130 384 + 125 
HDL-cholesterol 7 + 2 7 + 2 
Triglycerides 350 + 114 327 + 143 
Data (mg/dl) refer to measurements obtained after approximately 20 weeks 
of treatment. Statistical evaluation revealed a significant difference 
only between groups for the values of total serum cholesterol 
(*: ρ = 0.03). 
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FIGURE 1 
Serum cholesterol and serum tr ig lycer ides during the experimental 
period. Values represent means + SD for cholesterol (0, · ) and 
t r ig lycer ides (Δ,Α) in control (open symbols) and nifedipine-treated 
(closed symbols) groups. Signi f icant differences between both groups 
are also indicated: 
* : 0.01 < ρ < 0.05 
** : 0.001 < ρ < 0.01 
*** : ρ < 0.001 
— serum 
triglycerides 
(mg/dl ) 
4 0 0 
2 0 0 
12 IA 32 3Θ 
a g e ( w e e k s ) 
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ρ < 0.01. Likewise, average serum triglyceride level was significantly 
lower in the nifedipine group than in the control group: 213 + 109 vs 
306 + 96 mg/dl, ρ = 0.01. 
Serum lipoproteins, measured after approximately 20 weeks treatment 
at an age of 34 weeks, are given in Table 1. Clearly, the majority of 
cholesterol was bound to low density lipoprotein. Although total serum 
cholesterol was significantly lower in the nifedipine group than in the 
controls, this difference remained non-significant if the various 
lipoproteins classes were compared. 
Forty weeks-old WHHL rabbits in the control group had developed 
quite prominent Sudan-positive lesions, covering considerable areas of 
the various aortic segments (Figure 2, Table II). The daily intake of 
40 mg nifedipine over a period of 6 months did not affect atherogenes!s 
at all. Although considerable variation existed in the extent of 
atherosclerosis between rabbits, there was no indication for inhibition 
of plaque formation in any of the aortic segments investigated (Table II). 
VII.5 Discussion 
The WHHL rabbit is a new and probably unique model for human 
familial hypercholesterolemia, which shows persistently high serum 
TABLE II 
Area of Plaques as Percentage of Total Vessel Area 
control group (n=9) nifedipine group (n=9) 
Aortic arch 62 + 19 (40-86) 59 + 17 (31-81) 
Thoracic aorta 21 + 13 ( 6-46) 17 + 9 ( 2-32) 
Abdominal aorta 10 + 4 ( 5-14) 9 + 3 ( 5-14) 
Arteriae carotis 11 + 6 ( 5-20) 11 + 7 ( 4-23) 
Arteriae iliacae 2 + 3 ( 0 - 8 ) 1 + 1 ( 1 - 2 ) 
Truncus pulmonalis 3 + 4 ( 0-11) 1 + 1 ( 0 - 2 ) 
Values represent means + SD and (in brackets) range. No statistically 
significant differences were found between groups. 
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FIGURE 2 
An overview of Sudan-positive lesions in various aortic segments. From 
each rabbit the aortic arch (above), the thoracic aorta (left) and the 
abdominal aorta (right) are shown. 
cholesterol levels (Figure 1). A deficiency of low density lipoprotein 
receptors and an overproduction of low density lipoprotein lead to a 
massive increase in plasma low density lipoprotein (13), resulting in 
atherosclerosis at an early age. This study shows that treatment with 
nifedipine, started at an age of 14 weeks when no Sudan-positive lesions 
were present, did not prevent subsequent atherogenesis. The daily dose of 
40 mg nifedipine, resulting in quite high serum levels, should be 
sufficient for any therapeutic effect. Therefore, it can be concluded 
that this agent is uneffective in preventing atherosclerosis in WHHL 
rabbits. 
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It remains as yet unexplained why serum cholesterol levels in the 
control group exceed those observed in the nifedipine-treated animals 
(Figure 1). An anorectic effect of nifedipine could be postulated as a 
causal factor as the increase in body weight was slightly less in the 
experimental group, although the difference was not statistically 
significant. However, this explanation is rendered less probable by the 
finding that nifedipine did not influence serum cholesterol in diet-
induced hypercholesterolemia (2). It seems improbable that these 
relatively small variations at this high basic level of serum choles-
terol would influence atherogenes!s. Only rather dramatic decreases in 
serum cholesterol, as induced by partial ileal bypass surgery, will 
prevent formation of atherosclerotic lesions in WHHL rabbits (12). 
Our results disagree with those reported recently by Henry and 
Bently (2), who found a significant suppression of atherogenesis in 
cholesterol-fed rabbits. On the basis of their data they suggested 
that medication with calcium antagonists should be evaluated in children 
with familial hypercholesterolemia. In view of the results presented 
in our paper, which have been obtained with an animal model with 
hereditary hypercholesterolemia and thus resembles the human situation 
far more closely than the model which uses an alimentary hyper-
cholesterolemia, we feel that clinical trials using nifedipine for 
preventing atherosclerosis are not yet warranted. First, more evidence 
should be collected as to the effects and eventual working mechanisms 
in various forms of animal hypercholesterolemia. 
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SAMENVATTING 
Dit proefschrift beschrijft de effecten van een partiële dunne darm 
kortsluiting (PIB) en van medicamenteuze therapie op de hypercholesterol-
emie en athérosclérose in WHHL (Watanabe Heritable Hyperlipidemic) 
konijnen, een nieuw diermodel voor humane familiaire hypercholestero!-
ernie. 
Na een korte inleiding wordt in hoofdstuk I een literatuur-
overzicht gegeven over de behandeling van de humane familiaire 
hypercholesterolemie met een PIB. De bedoeling is de plaats van deze 
chirurgische behandelingsmethode te bepalen ten opzichte van gevestigde 
medicamenteuze therapieën. Benadrukt dient te worden dat het sluitende 
bewijs voor de zin van serum cholesterol verlagende maatregelen nog 
geleverd moet worden. Techniek, werkingsmechanisme, effecten en bij-
werkingen van de PIB in patiënten met familiaire hypercholesterolemie 
worden beschreven. In 101 heterozygote patiënten leidde PIB tot een 
blijvende serum cholesterol daling van 33 tot 40%, de operatie is echter 
niet zonder bijwerkingen. Het effect in 7 homozygote patiënten was 
minder uitgesproken: in 4 gevallen was er slechts een geringe daling, 
variërend van 13 tot 25%, terwijl het serum cholesterol in 3 patiënten 
niet werd beïnvloed. De oorzaak van deze uiteenlopende resultaten wordt 
besproken. 
Dierexperimenteel onderzoek naar athérosclérose werd tot zeer 
recentelijk voornamelijk verricht met modellen, waarin de hyper-
cholesterolemie alimentair werd geïnduceerd. Sinds enkele jaren bestaat 
er een diermodel voor humane familiaire hypercholesterolemie, waarin 
de hypercholesterolemie genetisch is bepaald: het WHHL konijn. Ten 
behoeve van ons onderzoek werd een stam van deze konijnen gefokt. 
Hoofdstuk II beschrijft de wijze waarop dit gebeurde, uitgaande van 
een aantal, door dr. Watanabe aan ons ter beschikking gestelde, WHHL 
konijnen. Er wordt ingegaan op het onderscheiden, op basis van het 
serum cholesterol gehalte zoals bepaald op een leeftijd van 12 weken, 
van heterozygote en homozygote konijnen en op het overervingspatroon. 
De hypercholesterolemie in homozygote konijnen is persisterend, in 
heterozygote dieren van voorbijgaande aard; beide vertonen een persis-
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terende hypertri glyceri demi е. 
Gezien de wisselende resultaten van de PIB bij homozygote patiënten, 
leek het zinvol om het effect van PIB bij homozygote WHHL konijnen na te 
gaan (hoofdstuk III). Het blijkt dat PIB een verlaging van serum choles-
terol, ten gevolge van een daling van zowel het VLDL-cholesterol als 
het LDL-cholesterol, induceert in alle geopereerde konijnen. De gemid-
delde serum cholesterol daling is 52%. Het veranderde electroforese-
patroon van serum lipoproteinen na PIB wordt beschreven. De oppervlakte 
van de atherosclerotische plaques in de verschillende vaten was 30 weken 
na PIB significant minder dan die in de groep konijnen welke een sham-
operatie had ondergaan. De geïnduceerde daling van serum cholesterol kan 
dus de atherogenese in WHHL konijnen remmen. 
Het bezit van de stam WHHL konijnen stelde ons in staat om twee 
modellen voor hypercholesterolernie, endogeen en exogeen, binnen één 
diersoort te vergelijken. In hoofdstuk IVworden de verschillen en 
overeenkomsten besproken tussen homozygote en heterozygote WHHL 
konijnen en een groep konijnen met alimentaire hypercholesterolemie. 
De nadruk hierbij ligt op karakterisering van het lipiden- en lipo-
proteinenpatroon met toepassing van biochemische methodieken. De hetero-
zygote WHHL konijnen hebben een voorbijgaande hypercholesterolemie en 
ontwikkelen geen atherosclerotische plaques. Homozygote WHHL konijnen 
en konijnen met een dieet-geinduceerde hypercholesterolemie vertonen 
een aanzienlijke plaque vorming. Ondanks de verschillende oorzaak van de 
hypercholesterolemie en de duidelijke verschillen in samenstelling en 
concentraties van de lipoproteinen, zijn er grote overeenkomsten in 
plaque vorming tussen beide groepen konijnen. In alle onderzochte 
groepen leidt PIB tot een daling van serum cholesterol waardoor plaque 
vorming kan worden voorkomen. 
Ofschoon PIB in homozygote WHHL konijnen resulteert in een 
gemiddelde daling van serum cholesterol met ruim 50%, is de resulterende 
concentratie van circulerend cholesterol nog steeds sterk verhoogd ten 
opzichte van die in normale konijnen. Derhalve werd nagegaan of door 
middel van medicamenteuze therapieën of door combinaties van therapieën 
een verdere serum cholesterol daling kan worden verkregen. In hoofdstuk 
V wordt verslag gedaan van het effect van de verschillende methoden van 
galzuurdrainge. De effecten van medicamenteuze behandeling met 
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cholestyramine zijn vergeleken met die van een 33% of een 50% kort-
sluiting van de dunne darm. Deze therapieën leiden tot een verlaging 
van serum cholesterol met, respectievelijk, 38, 55 en 52%. Toe-
voeging van cholestyramine na de operatie veroorzaakt een geringe 
additionele daling, resectie van het kortgesloten gedeelte heeft geen 
effect. 
Een ander principe om te komen tot verlaging van serum cholesterol 
is de toepassing van remmers van de cholesterol synthese, in het bijzonder 
van het enzym 3-hydroxy-3-methylglutaarzuur coenzym A (HMG CoA) 
synthetase. Toevoeging van HMG aan het drinkwater van homozygote WHHL 
konijnen verlaagde het serum cholesterol met 39% (hoofdstuk VI). Een 
combinatie van cholestyramine en HMG vertoonde geen groter effect dan 
toepassing van elk medicijn afzonderlijk. Echter, intra-peritoneale 
injectie van HMG na PIB resulteerde in een significante verdere daling 
van serum cholesterol. 
Tenslotte wordt in hoofdstuk VII het effect van de calcium anta-
gonist nifedipine nagegaan. Volgens recente literatuur zou nifedipine 
de vorming van atherosclerotische plaques in konijnen met een alimen-
taire hypercholesterolemie verminderen. Uit onze resultaten blijkt dat 
nifedipine de atherogenese in WHHL konijnen niet beïnvloedt en geconclu-
deerd wordt dan ook dat klinische toepassingen van dit medicijn, zoals 
door anderen voorgesteld ten behoeve van patiënten met familiaire 
hypercholesterolemie, voorbarig zijn. 
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STELLINGEN 
1. Het effect van een partiële dunne darm kortsluiting, voor 
humane familiaire hypercholesterolemie, op de leverhistologie 
is onvoldoende bestudeerd (dit proefschrift). 
2. Heterozygote WHHL konijnen vertonen alleen op jonge leeftijd 
een hypercholesterolemie (dit proefschrift), 
3. Op grond van de huidige inzichten omtrent het werkingsmechanisme 
van de partiële dunne darm kortsluiting, bestaat er een 
discrepantie tussen de geringe LDL-receptor activiteit en de 
sterke serum cholesterol daling na een partiële dunne darm 
kortsluiting bij WHHL konijnen (dit proefschrift). 
4. Clinical trials met nifedipine om de atherogenese te remmen 
zijn voorbarig (dit proefschrift). 
5. Verschillende vormen van hyperlipoproteïnemie kunnen bij het 
konijn tot een zelfde vorm van athérosclérose leiden (dit 
proefschrift). 
6. De consequenties van een verhoogde activiteit van het z.g.n. 
leverlipase bij WHHL konijnen dient verder te worden onderzocht. 
7. Mediale epicondyle fracturen kunnen een pseudo-arthrose 
veroorzaken zonder klachten te geven. 
8. Het effect van ascal en persantin tijdens coronair-dilatatie 
verdient, gezien de gunstige resultaten tijdens coronaire 
bypass chirurgie, nader onderzoek (J.H. Chesebro, I.P. Clements, 
V. Fuster. N. Engl. J. Med. 1982; 307: 73-78). 
9. Gezien het feit dat maximale stimulering van de collageensynthese 
rond danmaden optreedt in de eerste week na operatie, is het 
aanvechtbaar dat Stromberg en Klein juist deze eerste week 
buiten beschouwing laten wanneer zij de vorming van nieuw 
collageen gedurende de genezing van darmnaden bestuderen 
(B.V. Stromberg en L. Klein. Dis. Colon Rectum 1982; 25: 301-304. 
H. Jiborn, J. Ahonen en B. Zederfeldt. Am. J. Surg. 1980; 139: 
406-413). 
10. Gezien de complicaties van de jejuno-ileal bypass, verdient een 
gastric bypass de voorkeur als chirurgische behandelingsmethode 
voor morbide obesitas (W.O. Griffen et al. Surgery 1983; 157: 
301-308). 
11. De zeer grote selectiescherpte die mogelijk is bij kunstmatige 
inseminatie in combinatie met embryo-transplantatie vergroot de 
kans op genenverlies in de nederlandse veestapel. 
12. De z.g.n. roeirug kan worden voorkómen door eerste-jaars roeiers 
naast het boordroeien ook te laten skiffen. 


